<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="fabry" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">fabry</book-part-id>
      <title-group>
        <title>Fabry Disease</title>
        <alt-title alt-title-type="alt-title">Synonyms: Anderson-Fabry Disease, Alpha-Galactosidase A Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mehta</surname>
            <given-names>Atul</given-names>
          </name>
          <degrees>MA, MD, FRCP, FRCPath</degrees>
          <aff>Director, Lysosomal Storage Disorders Unit<break/>Consultant Haematologist, Royal Free Hospital<break/>University College London School of Medicine<break/>London, United Kingdom</aff>
          <email>atul.mehta1@nhs.net</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hughes</surname>
            <given-names>Derralynn A</given-names>
          </name>
          <degrees>MA, DPhil, FRCP, FRCPath</degrees>
          <aff>Senior Lecturer Haematology, Lysosomal Storage Disorders Unit <break/>Department of Haematology <break/>Royal Free Hospital <break/>University College London <break/>London, United Kingdom</aff>
          <email>rmgvdah@ucl.ac.uk</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>5</day>
          <month>8</month>
          <year>2002</year>
        </date>
        <date date-type="updated">
          <day>5</day>
          <month>1</month>
          <year>2017</year>
        </date>
        <date date-type="revised">
          <day>2</day>
          <month>1</month>
          <year>2004</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="xl-nystag" document-type="chapter"><italic toggle="yes">FRMD7</italic>-Related Infantile Nystagmus</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="fsh" document-type="chapter">Facioscapulohumeral Muscular Dystrophy</related-object>
      <abstract id="fabry.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (&#x003b1;-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% &#x003b1;-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype.</p>
          <p>In contrast, males with greater than 1% &#x003b1;-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Identification of deficient &#x003b1;-Gal A enzyme activity in plasma, isolated leukocytes, and/or cultured cells is the most efficient and reliable method of diagnosing Fabry disease in males. Identification of a hemizygous <italic toggle="yes">GLA</italic> pathogenic variant by molecular genetic testing confirms the diagnosis in a male proband. Identification of a heterozygous <italic toggle="yes">GLA</italic> pathogenic variant by molecular genetic testing confirms the diagnosis in a heterozygous female.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations</italic>: Diphenylhydantoin, carbamazepine, or gabapentin to reduce pain (acroparesthesia); ACE inhibitors or angiotensin receptor blockers to reduce proteinuria; chronic hemodialysis and/or renal transplantation for ESRD.</p>
          <p><italic toggle="yes">Prevention of primary complications:</italic> The role of enzyme replacement therapy (ERT) in the long-term prophylaxis of renal, cardiac, and CNS manifestations is unproven; however, experts recommend that ERT be initiated as early as possible in all males with Fabry disease (including children and those with ESRD undergoing dialysis and renal transplantation) and in females with significant disease because all are at high risk for cardiac, cerebrovascular, and renal complications.</p>
          <p><italic toggle="yes">Prevention of secondary complications</italic>: Prophylaxis for renovascular disease, ischemic heart disease, and cerebrovascular disease as for the general population.</p>
          <p><italic toggle="yes">Surveillance</italic>: Annual or more frequent assessment of renal function; annual cardiology and audiology evaluations; biennial brain MRI/MRA.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid</italic>: Smoking.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk</italic>: Early identification of affected relatives by molecular genetic testing if the pathogenic variant in the family is known in order to initiate ERT as early as possible in affected individuals.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Fabry disease is inherited in an X-linked manner. In a family with more than one affected individual, the mother of an affected male is an obligate heterozygote (carrier). If only one male in a family is affected, his mother is likely heterozygous; rarely, a single affected male in a family may have a <italic toggle="yes">de novo</italic> pathogenic variant. A heterozygous female has a 50% chance of transmitting the <italic toggle="yes">GLA</italic> pathogenic variant in each pregnancy. An affected male transmits his pathogenic variant to all of his daughters. Heterozygote (carrier) testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variant in a family is known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="fabry.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="fabry.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_fabry.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Fabry Disease: Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_fabry.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Classic Fabry disease</p></list-item><list-item><p>Atypical and late-onset variants of Fabry disease</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="fabry.Diagnosis">
        <title>Diagnosis</title>
        <sec id="fabry.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Fabry disease <bold>should be suspected</bold> in males and females with the following clinical features:</p>
          <list list-type="bullet">
            <list-item>
              <p>Periodic crises of severe pain in the extremities (acroparesthesia)</p>
            </list-item>
            <list-item>
              <p>Vascular cutaneous lesions (angiokeratomas)</p>
            </list-item>
            <list-item>
              <p>Sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis)</p>
            </list-item>
            <list-item>
              <p>Characteristic corneal and lenticular opacities</p>
            </list-item>
            <list-item>
              <p>Unexplained stroke</p>
            </list-item>
            <list-item>
              <p>Unexplained left ventricular hypertrophy</p>
            </list-item>
            <list-item>
              <p>Renal insufficiency of unknown etiology including unexplained proteinuria or microalbuminuria</p>
            </list-item>
          </list>
        </sec>
        <sec id="fabry.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>A diagnostic algorithm is provided in <xref ref-type="bibr" rid="fabry.REF.gal.2011">Gal et al [2011]</xref> (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063537/">full text</ext-link>) and an approach to investigations of variants of unknown significance described in <xref ref-type="bibr" rid="fabry.REF.smid.2014.400">Smid et al [2014]</xref>.</p>
          <p><bold>Male proband.</bold> The diagnosis of Fabry disease <bold>is established</bold> in a male proband by:</p>
          <list list-type="bullet">
            <list-item>
              <p>Identification of deficient alpha-galactosidase A (&#x003b1;-Gal A) enzyme activity in plasma, isolated leukocytes, and/or cultured cells. The test is a fluorometric assay and uses the substrate 4-methylumbelliferyl-&#x003b1;-D-galactopyranoside.</p>
              <list list-type="bullet">
                <list-item>
                  <p>Males with classic Fabry disease have &#x0003c;1% &#x003b1;-Gal A enzyme activity.</p>
                </list-item>
                <list-item>
                  <p>Males with atypical Fabry disease have residual enzyme activity &#x0003e;1% of normal.</p>
                </list-item>
              </list>
              <p>Note: Both plasma and leukocyte enzyme activity should be assayed, as some pathogenic variants (e.g., <xref ref-type="table" rid="fabry.T.selected_gla_variants">p.Asn215Ser</xref>) affect intracellular trafficking or packaging/secretion of the enzyme, such that the reduction in enzyme activity in plasma is more marked than the reduction in enzyme activity in leukocytes.</p>
            </list-item>
            <list-item>
              <p>Identification of a hemizygous pathogenic variant in <italic toggle="yes">GLA</italic> by molecular genetic testing (see <xref ref-type="table" rid="fabry.T.molecular_genetic_testing_used_i">Table 1</xref>).</p>
            </list-item>
          </list>
          <p><bold>Female proband.</bold> The diagnosis of Fabry disease <bold>is established</bold> in a female proband by identification of a heterozygous pathogenic variant in <italic toggle="yes">GLA</italic> by molecular genetic testing (see <xref ref-type="table" rid="fabry.T.molecular_genetic_testing_used_i">Table 1</xref>).</p>
          <p>Note: Measurement of &#x003b1;-Gal A enzyme activity is unreliable for identification of heterozygous females. Although demonstration of markedly decreased &#x003b1;-Gal A enzyme activity in a female is diagnostic of the heterozygous state, some heterozygotes have &#x003b1;-Gal A activity in the normal range.</p>
          <sec id="fabry.Molecular_Testing">
            <title>Molecular Testing</title>
            <p>Molecular testing approaches can include <bold>single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive genomic testing</bold>.</p>
            <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">GLA</italic> is performed first and followed by gene-targeted deletion/duplication analysis if no pathogenic variant is found.</p>
            <p>Targeted analysis for the p.Ala143Pro pathogenic variant can be performed first in individuals from Nova Scotia (incidence 1:15,000).</p>
            <p>Targeted analysis for the IVS4+919G&#x0003e;A pathogenic variant can be performed first in individuals of Chinese ancestry with atypical presentation (see <xref ref-type="sec" rid="fabry.Molecular_Genetics">Molecular Genetics</xref>) [Liu et al].</p>
            <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">GLA</italic> and other genes of interest (see <xref ref-type="sec" rid="fabry.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost while limiting secondary findings. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
            <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
            <p><bold>More comprehensive genomic testing</bold> may be considered if single-gene testing (and/or use of a multi-gene panel) has not confirmed a diagnosis in an individual with features of Fabry disease. Such testing may include exome sequencing, genome sequencing, and mitochondrial sequencing. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            <table-wrap id="fabry.T.molecular_genetic_testing_used_i" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Molecular Genetic Testing Used in Fabry Disease</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">GLA</italic>
                    </td>
                    <td headers="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">~95%&#x000a0;<sup>4</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5,&#x000a0;6</sup></td>
                    <td headers="hd_h_fabry.T.molecular_genetic_testing_used_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">~5%&#x000a0;<sup>7</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="fabry.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="fabry" object-id="fabry.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="fabry.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="fabry.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
                </fn>
                <fn id="fabry.TF.1.3">
                  <label>3. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="fabry.TF.1.4">
                  <label>4. </label>
                  <p>Lack of amplification by PCR prior to sequence analysis can suggest a putative (multi)exon or whole-gene deletion on the X chromosome in affected males; confirmation requires additional testing by gene-targeted deletion/duplication analysis</p>
                </fn>
                <fn id="fabry.TF.1.5">
                  <label>5. </label>
                  <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used can include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
                </fn>
                <fn id="fabry.TF.1.6">
                  <label>6. </label>
                  <p>Deletion/duplication analysis can be used (a) to confirm a putative exon/whole-gene deletion in males after failure to amplify by PCR in sequence analysis and (b) to identify partial- and whole-gene deletions in females.</p>
                </fn>
                <fn id="fabry.TF.1.7">
                  <label>7. </label>
                  <p><xref ref-type="bibr" rid="fabry.REF.bernstein.1989.1390">Bernstein et al [1989]</xref>, <xref ref-type="bibr" rid="fabry.REF.kornreich.1990.9319">Kornreich et al [1990]</xref></p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Test characteristics.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/v20/n2/full/ejhg2011178a.html">Clinical utility gene card: Fabry disease</ext-link> [<xref ref-type="bibr" rid="fabry.REF.gal.2012.20">Gal et al 2012</xref>] for information on test characteristics including sensitivity and specificity.</p>
          </sec>
          <sec id="fabry.Additional_Testing">
            <title>Additional Testing</title>
            <p>
              <bold>Biomarkers</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Plasma globotriaosylsphingosine (lyso-Gb3) (the lyso derivative of the accumulated substrate) levels appear to correlate with disease severity and to decline with enzyme replacement therapy [<xref ref-type="bibr" rid="fabry.REF.aerts.2008.2812">Aerts et al 2008</xref>].</p>
              </list-item>
              <list-item>
                <p>Urinary levels of lyso-Gb3 derivatives also correlate with disease severity [<xref ref-type="bibr" rid="fabry.REF.aurayblais.2015.195">Auray-Blais et al 2015</xref>].</p>
              </list-item>
              <list-item>
                <p>Plasma lyso-Gb3 levels are higher in affected males than females.</p>
              </list-item>
              <list-item>
                <p>Identification of elevated plasma and urinary lyso-Gb3 can confirm the diagnosis in an individual with a <italic toggle="yes">GLA</italic> variant of uncertain significance identified by molecular genetic testing or late-onset disease manifestations. <xref ref-type="bibr" rid="fabry.REF.niemann.2014.8">Niemann et al [2014]</xref> reported that individuals with a novel variant and organ involvement consistent with Fabry disease had lyso-Gb3 levels &#x02265;2.7ng/mL; Individuals with a novel <italic toggle="yes">GLA</italic> variant and no organ involvement had lyso-Gb3 levels &#x0003c;2.7 ng/mL.</p>
              </list-item>
            </list>
            <p>Note: There are no universally recognized biomarkers of Fabry disease.</p>
            <p><bold>Endomyocardial biopsy.</bold> Identification of characteristic globotriaosylceramide (GL-3) inclusions on endomyocardial biopsy can establish a diagnosis in an individual with left ventricular hypertrophy and a <italic toggle="yes">GLA</italic> variant of uncertain significance [<xref ref-type="bibr" rid="fabry.REF.hsu.2014.96">Hsu et al 2014</xref>].</p>
          </sec>
        </sec>
      </sec>
      <sec id="fabry.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="fabry.Clinical_Description">
          <title>Clinical Description</title>
          <p>Fabry disease encompasses a spectrum of phenotypes ranging from the severe classic phenotype to atypical forms. The classic phenotype is probably the most common, although atypical forms of the disease, which present later in life, may be underdiagnosed [<xref ref-type="bibr" rid="fabry.REF.sachdev.2002.1407">Sachdev et al 2002</xref>, <xref ref-type="bibr" rid="fabry.REF.nakao.2003.801">Nakao et al 2003</xref>].</p>
          <p>The Fabry Outcome Survey (FOS) and the Fabry Registry, multicenter international initiatives designed to examine the natural history of Fabry disease and the effects of enzyme replacement therapy, are an important source of new data on the disease [<xref ref-type="bibr" rid="fabry.REF.mehta.2004.236">Mehta et al 2004</xref>, <xref ref-type="bibr" rid="fabry.REF.eng.2007.184">Eng et al 2007</xref>].</p>
          <table-wrap id="fabry.T.major_manifestations_in_classic" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Major Manifestations in Classic and Atypical Fabry Disease</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1"/>
                  <th id="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Classic</th>
                  <th id="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Renal Variant</th>
                  <th id="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Cardiac Variant</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">
                    <bold>Age at onset</bold>
                  </td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">4-8 yrs</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;25 yrs</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;40 yrs</td>
                </tr>
                <tr>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">
                    <bold>Average age of death</bold>
                  </td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">41 yrs</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;60 yrs</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;60 yrs</td>
                </tr>
                <tr>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" rowspan="8" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Manifestation</bold>
                  </td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">Angiokeratoma</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">++</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                </tr>
                <tr>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Acroparesthesia</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">++</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;/+</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                </tr>
                <tr>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Hypohidrosis/anhidrosis</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">++</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;/+</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                </tr>
                <tr>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Corneal/lenticular opacity</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                </tr>
                <tr>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Cardiac disease</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">LVH/ischemia</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">LVH</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">LVH/cardiomyopathy</td>
                </tr>
                <tr>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Cerebrovascular disease</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">TIA/stroke</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                </tr>
                <tr>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Renal disease</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">ESRD</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">ESRD</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Proteinuria</td>
                </tr>
                <tr>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_1" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Residual &#x003b1;-Gal A enzyme activity</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;1%</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;1%</td>
                  <td headers="hd_h_fabry.T.major_manifestations_in_classic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;1%</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="fabry.TF.2.1">
                <label>+ </label>
                <p>= present</p>
              </fn>
              <fn>
                <p>&#x02013; = absent</p>
              </fn>
              <fn>
                <p>&#x003b1;-Gal A = alpha-galactosidase A</p>
              </fn>
              <fn>
                <p>ESRD = end-stage renal disease</p>
              </fn>
              <fn>
                <p>LVH = left ventricular hypertrophy</p>
              </fn>
              <fn>
                <p>TIA = transient ischemic attack</p>
              </fn>
              <fn>
                <p><xref ref-type="bibr" rid="fabry.REF.mehta.2004.236">Mehta et al [2004]</xref>, <xref ref-type="bibr" rid="fabry.REF.eng.2007.184">Eng et al [2007]</xref></p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <sec id="fabry.Classic_Fabry_Disease">
            <title>Classic Fabry Disease</title>
            <p>Onset of symptoms usually occurs in childhood or adolescence with the appearance of angiokeratomas, periodic crises of severe pain in the extremities (acroparesthesia), hypohidrosis, and the characteristic corneal and lenticular opacities. Although proteinuria may be detected early, renal insufficiency usually occurs in the third to fifth decade of life. Death occurs from complications of renal disease, cardiac involvement, and/or cerebrovascular disease.</p>
            <p><bold>Angiokeratomas</bold> are often one of the earliest manifestations of Fabry disease. They appear as clusters of punctate, dark red to blue-black angiectases in the superficial layers of the skin. The lesions may be flat or slightly raised and do not blanch with pressure. Slight hyperkeratosis is notable in larger lesions.</p>
            <p>The clusters of lesions are most dense between the umbilicus and the knees; they most commonly involve the hips, back, thighs, buttocks, penis, and scrotum, and tend to be bilaterally symmetric. The oral mucosa, conjunctiva, and other mucosal areas are commonly involved. A wide variation in the distribution pattern and density of the lesions may occur. Examination of the skin, especially the scrotum and umbilicus, may reveal the presence of isolated lesions. Data from 714 affected individuals (345 males, 369 females) in the FOS [<xref ref-type="bibr" rid="fabry.REF.orteu.2007.331">Orteu et al 2007</xref>] suggest that they are present in 66% of males (36% of females).</p>
            <p>The number and size of these cutaneous vascular lesions progressively increase with age. The presence of angiokeratoma correlated with the severity of the systemic disease manifestations [<xref ref-type="bibr" rid="fabry.REF.zampetti.2012.712">Zampetti et al 2012</xref>].</p>
            <p><bold>Acroparesthesia</bold> occurs as episodic crises of agonizing, burning pain in the distal extremities that most often begin in childhood or early adolescence and signal clinical onset of the disease. These crises last from minutes to several days and are usually triggered by exercise, fatigue, emotional stress, or rapid changes in temperature and humidity. Often the pain radiates to the proximal extremities and other parts of the body. Attacks of abdominal or flank pain may simulate appendicitis or renal colic.</p>
            <p>The crises usually decrease in frequency and severity with increasing age; however, in some affected individuals, the frequency increases and the pain can be so excruciating and incapacitating that the individual may contemplate suicide.</p>
            <p><bold>Hypohidrosis or anhidrosis</bold> is an early and almost constant finding. Hyperhidrosis also occurs; in the FOS it was seen in 12% of females and 6.4% of males [<xref ref-type="bibr" rid="fabry.REF.lidove.2006.1053">Lidove et al 2006</xref>].</p>
            <p><bold>Cornea verticillata,</bold> the characteristic corneal opacity that is observed only by slit-lamp microscopy, is found in affected males and most heterozygous females. The earliest corneal lesion is a diffuse haziness in the subepithelial layer. With time, the opacities appear as whorled streaks extending from a central vortex to the periphery of the cornea. The whorl-like opacities, typically inferior and cream colored, range from white to golden brown and may be very faint [<xref ref-type="bibr" rid="fabry.REF.nguyen.2005.164">Nguyen et al 2005</xref>]. In the FOS, cornea verticillata was present in 77% of females and 73% of males undergoing detailed ophthalmologic examination [<xref ref-type="bibr" rid="fabry.REF.sodi.2007.210">Sodi et al 2007</xref>].</p>
            <p><bold>Lenticular changes</bold> are present in approximately 30% of affected males and include a granular anterior capsular or subcapsular deposit and a unique, possibly pathognomonic, lenticular opacity (the "Fabry cataract"). The cataracts, which are best observed through a dilated pupil by slit-lamp examination using retroillumination, are whitish, spoke-like deposits of fine granular material on or near the posterior lens capsule. These lines usually radiate from the central part of the posterior cortex. The corneal and lenticular opacities do not interfere with visual acuity.</p>
            <p><bold>Other ocular features.</bold> Aneurysmal dilatation and tortuosity of conjunctival and retinal vessels also occur; while not specific for Fabry disease, vessel tortuosity is observed more frequently in individuals with a higher disease severity score [<xref ref-type="bibr" rid="fabry.REF.sodi.2007.210">Sodi et al 2007</xref>, <xref ref-type="bibr" rid="fabry.REF.allen.2010.1602">Allen et al 2010</xref>]. Data from the FOS demonstrates that the ocular changes correlate well with overall disease severity and with genotype [<xref ref-type="bibr" rid="fabry.REF.pitz.2015.e0120814">Pitz et al 2015</xref>].</p>
            <p><bold>Cardiac disease.</bold> Mitral insufficiency may be present in childhood or adolescence. Left ventricular enlargement and conduction abnormalities are early findings. Left ventricular hypertrophy, often associated with hypertrophy of the interventricular septum and appearing similar to hypertrophic cardiomyopathy (HCM), is progressive and occurs earlier in males than females [<xref ref-type="bibr" rid="fabry.REF.kampmann.2005.15">Kampmann et al 2005</xref>]. Cardiac disease is present in most males with the classic phenotype by middle age and is the major cause of morbidity and mortality in those who have undergone dialysis or transplantation for treatment of end-stage renal disease (ESRD).</p>
            <p>ECG changes including ST segment changes, T-wave inversion, and dysrhythmias such as a short PR interval and intermittent supraventricular tachycardias may be caused by infiltration of the conduction system. Echocardiography demonstrates an increased thickness of the interventricular septum and the left ventricular posterior wall [<xref ref-type="bibr" rid="fabry.REF.pieroni.2006.1663">Pieroni et al 2006</xref>]. Magnetic resonance studies using gadolinium demonstrated late enhancement areas, corresponding to myocardial fibrosis and associated with decreased regional functioning as assessed by strain and strain-rate imaging [<xref ref-type="bibr" rid="fabry.REF.moon.2003.2151">Moon et al 2003</xref>, <xref ref-type="bibr" rid="fabry.REF.weidemann.2005.1221">Weidemann et al 2005</xref>]. T<sub>1</sub> mapping illustrates intramural fat deposition and posterior wall fibrosis [<xref ref-type="bibr" rid="fabry.REF.sado.2013.392">Sado et al 2013</xref>].</p>
            <p>Among 714 predominantly adult individuals in the FOS [<xref ref-type="bibr" rid="fabry.REF.linhart.2007.1228">Linhart et al 2007</xref>], angina, palpitations/arrhythmia, and exertional dyspnea were found in 23%-27% of males and 22%-25% of females. Hypertension, angina pectoris, myocardial ischemia and infarction, congestive heart failure, and severe mitral regurgitation are late signs. Hypertension was found in more than 50% of males and more than 40% of females in the FOS [<xref ref-type="bibr" rid="fabry.REF.kleinert.2006.782">Kleinert et al 2006</xref>].</p>
            <p><bold>Cerebrovascular manifestations</bold> result primarily from multifocal small vessel involvement and may include thrombosis, transient ischemic attacks (TIA), basilar artery ischemia and aneurysm, seizures, hemiplegia, hemianesthesia, aphasia, labyrinthine disorders, or frank cerebral hemorrhage [<xref ref-type="bibr" rid="fabry.REF.politei.2006.103">Politei &#x00026; Capizzano 2006</xref>]. FOS data indicate that stroke or TIA occur in approximately 13% of affected individuals overall (15% males, 11.5% females) [<xref ref-type="bibr" rid="fabry.REF.ginsberg.2006.57">Ginsberg et al 2006</xref>]. The Fabry Registry has reported that cerebrovascular manifestations are often a presenting feature of Fabry disease and may be more frequent than previously recognized [<xref ref-type="bibr" rid="fabry.REF.sims.2009.788">Sims et al 2009</xref>]. <xref ref-type="bibr" rid="fabry.REF.rolfs.2005.1794">Rolfs et al [2005]</xref> reported that in Germany a <italic toggle="yes">GLA</italic> pathogenic variant was identified in 21 of 432 males (4.9%) and seven of 289 females (2.4%) age 18-55 years suffering cryptogenic stroke. However, other studies have not confirmed such a high prevalence [<xref ref-type="bibr" rid="fabry.REF.brouns.2010.863">Brouns et al 2010</xref>, <xref ref-type="bibr" rid="fabry.REF.wozniak.2010.78">Wozniak et al 2010</xref>, <xref ref-type="bibr" rid="fabry.REF.rolfs.2013.340">Rolfs et al 2013</xref>]. Thromboembolic events are more common among individuals with Fabry disease who also have the factor V Leiden variant [<xref ref-type="bibr" rid="fabry.REF.lenders.2015.1009">Lenders et al 2015</xref>].</p>
            <p>In addition, a distinct neurologic phenotype including decreased motor performance and nonmotor neurologic manifestations has been described. Individuals with Fabry disease showed slower gait and transfer speed, poorer fine manual dexterity, and slower hand speed than controls. Affected individuals had an increased incidence of depression, pain, and daytime sleepiness but did not exhibit extrapyramidal motor features or signs of significant cognitive impairment [<xref ref-type="bibr" rid="fabry.REF.l_hle.2015.1454">L&#x000f6;hle et al 2015</xref>].</p>
            <p><bold>Renal involvement.</bold> Progressive glycosphingolipid accumulation in the kidney interferes with renal function, resulting in azotemia and renal insufficiency.</p>
            <p>During childhood and adolescence, protein, casts, red cells, and birefringent lipid globules with characteristic "Maltese crosses" can be observed in the urinary sediment. Proteinuria, isosthenuria, and a gradual deterioration of tubular reabsorption, secretion, and excretion occur with advancing age. Polyuria and a syndrome similar to vasopressin-resistant diabetes insipidus occasionally develop.</p>
            <p>Gradual deterioration of renal function and the development of azotemia usually occur in the third to fifth decade of life, although ESRD has been reported in the second decade. Death most often results from ESRD unless chronic hemodialysis or renal transplantation is undertaken. The mean age at death of males not treated for ESRD is 41 years, but occasionally an untreated male with the classic phenotype survives into the seventh decade.</p>
            <p><bold>Other clinical features.</bold> In addition to the major clinical features described above, males and females with the classic phenotype may have gastrointestinal, auditory, pulmonary, and other manifestations.</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Gastrointestinal.</bold> Glycosphingolipid deposition in intestinal small vessels and in the autonomic ganglia of the bowel may cause episodic diarrhea, nausea, vomiting, bloating, cramping abdominal pain, and/or intestinal malabsorption [<xref ref-type="bibr" rid="fabry.REF.hoffmann.2007.1447">Hoffmann et al 2007</xref>]. Achalasia and jejunal diverticulosis, which may lead to perforation of the small bowel, have been described. Radiographic studies may reveal thickened, edematous colonic folds, mild dilatation of the small bowel, a granular-appearing ileum, and the loss of haustral markings throughout the colon.</p>
              </list-item>
              <list-item>
                <p><bold>Pulmonary.</bold> Several affected individuals have had pulmonary involvement, manifest clinically as chronic bronchitis, wheezing, or dyspnea. Primary pulmonary involvement has been reported in the absence of cardiac or renal disease. Pulmonary function studies may show an obstructive component [<xref ref-type="bibr" rid="fabry.REF.magage.2007.790">Magage et al 2007</xref>] which has been demonstrated to stabilize with enzyme replacement therapy (ERT) [<xref ref-type="bibr" rid="fabry.REF.odler.2016.13">Odler et al 2016</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Vascular.</bold> Pitting edema of the lower extremities may be present in adulthood in the absence of hypoproteinemia, varices, or other clinically significant vascular disease. Although the pitting edema is initially reversible, progressive glycosphingolipid deposition in the lymphatic vessels and lymph nodes results in irreversible lymphedema requiring treatment with compression hosiery. Varicosities, hemorrhoids, and priapism have also been reported.</p>
              </list-item>
              <list-item>
                <p><bold>Cranial nerve VIII involvement.</bold> High-frequency hearing loss, tinnitus, and dizziness have been reported [<xref ref-type="bibr" rid="fabry.REF.hegemann.2006.654">Hegemann et al 2006</xref>].</p>
              </list-item>
              <list-item>
                <p><bold>Psychological.</bold> Depression, anxiety, severe fatigue, and other psychosocial manifestations lead to decreased quality of life in many affected individuals [<xref ref-type="bibr" rid="fabry.REF.cole.2007.943">Cole et al 2007</xref>].</p>
              </list-item>
            </list>
          </sec>
          <sec id="fabry.Heterozygous_Carrier_Females">
            <title>Heterozygous (Carrier) Females</title>
            <p>The clinical manifestations in heterozygous females range from asymptomatic throughout a normal life span to as severe as affected males. Variation in clinical manifestations is attributed to random X-chromosome inactivation [<xref ref-type="bibr" rid="fabry.REF.deegan.2006.347">Deegan et al 2006</xref>]. More severely affected females are more likely to express the X chromosome with the <italic toggle="yes">GLA</italic> pathogenic variant in affected organs [<xref ref-type="bibr" rid="fabry.REF.echevarria.2016.44">Echevarria et al 2016</xref>].</p>
            <p>Most heterozygous females from families in which affected males have the classic phenotype have a milder clinical course and better prognosis than affected males.</p>
            <p>Mild manifestations include the characteristic cornea verticillata (70%-90%) and lenticular opacities that do not impair vision; acroparesthesia (50%-90%); angiokeratomas (10%-50%) that are usually isolated or sparse; and hypohidrosis. In addition, heterozygotes may have chronic abdominal pain and diarrhea [<xref ref-type="bibr" rid="fabry.REF.gupta.2005.261">Gupta et al 2005</xref>].</p>
            <p>With advancing age, heterozygotes may develop mild to moderate enlargement of the left heart (left ventricular hypertrophy) and valvular disease. More serious manifestations include significant left ventricular hypertrophy, cardiomegaly, myocardial ischemia, infarction, and cardiac arrhythmias [<xref ref-type="bibr" rid="fabry.REF.shah.2005.842">Shah et al 2005</xref>, <xref ref-type="bibr" rid="fabry.REF.deegan.2006.347">Deegan et al 2006</xref>, <xref ref-type="bibr" rid="fabry.REF.wilcox.2008.112">Wilcox et al 2008</xref>].</p>
            <p>The occurrence of cerebrovascular disease including transient ischemic attacks and cerebrovascular accidents is consistent with the microvascular pathology of the disease [<xref ref-type="bibr" rid="fabry.REF.macdermot.2001.769">MacDermot et al 2001</xref>, <xref ref-type="bibr" rid="fabry.REF.whybra.2001.715">Whybra et al 2001</xref>, <xref ref-type="bibr" rid="fabry.REF.galanos.2002.575">Galanos et al 2002</xref>].</p>
            <p>Renal findings in heterozygotes include isosthenuria, the presence of erythrocytes, leukocytes, and granular and hyaline casts in the urinary sediment, and proteinuria. According to the United States and European dialysis and transplantation registries, approximately 10% of heterozygotes develop renal failure requiring dialysis or transplantation.</p>
            <p>Excessive guilt, fatigue, occupational difficulty, suicidal ideation, and depression have been noted in heterozygotes [<xref ref-type="bibr" rid="fabry.REF.sadek.2004.199">Sadek et al 2004</xref>].</p>
            <p><bold>Life expectancy and cause of death.</bold> Based on data from the Fabry Registry, 75 of 1422 males and 12 of 1426 females were reported to have died. The 87 deceased individuals were diagnosed at a much older age than other individuals in the Fabry Registry. The life expectancy of males with Fabry disease was 58.2 years, compared with 74.7 years in the general population of the United States. The life expectancy of females with Fabry disease was 75.4 years, compared with 80.0 years in the United States general population. The most common cause of death among both genders was cardiovascular disease [<xref ref-type="bibr" rid="fabry.REF.waldek.2009.790">Waldek et al 2009</xref>]. Most individuals (57%) who died of cardiovascular disease had previously received renal replacement therapy (e.g., dialysis or transplantation). In the FOS, the principal causes of death among 181 affected relatives (most of whom had died before 2001) were renal failure in males (42%) and cerebrovascular disease in females (25%) [<xref ref-type="bibr" rid="fabry.REF.mehta.2009.548">Mehta et al 2009</xref>]. In contrast, of the 42 individuals enrolled in the FOS whose deaths were reported between 2001 and 2007, cardiac disease was the main cause of death in both males (34%) and females (57%). The possible impact of ERT on life expectancy is discussed in Management, <xref ref-type="sec" rid="fabry.Prevention_of_Primary_Manifestatio">Prevention of Primary Manifestations</xref>.</p>
          </sec>
          <sec id="fabry.Atypical_Variants_of_Fabry_Disease">
            <title>Atypical Variants of Fabry Disease</title>
            <p><bold>Cardiac variant.</bold> Males and females with cardiac disease are asymptomatic during most of their lives and typically present in the sixth to eighth decade of life with left ventricular hypertrophy, hypertrophic cardiomyopathy (HCM), conduction disturbances and arrhythmias. Screening of males with "late-onset" hypertrophic cardiomyopathy (HCM) found that 6.3% who were diagnosed at or after age 40 years and 1.4% of males who were diagnosed before age 40 years had Fabry disease confirmed by identification of low &#x003b1;-Gal A enzyme activity and a <italic toggle="yes">GLA</italic> hemizygous pathogenic variant [<xref ref-type="bibr" rid="fabry.REF.sachdev.2002.1407">Sachdev et al 2002</xref>]. Magnetic resonance imaging of the heart typically shows late enhancement of the posterior wall with gadolinium reflecting posterior wall fibrosis demonstrated in postmortem specimens [<xref ref-type="bibr" rid="fabry.REF.moon.2003.2151">Moon et al 2003</xref>]. The incidence of cardiac complications is similar in individuals with the atypical Fabry cardiac variant and individuals with classic Fabry disease [<xref ref-type="bibr" rid="fabry.REF.patel.2015.961">Patel et la 2015</xref>].</p>
            <p>Individuals with the cardiac variant exhibit mild to moderate proteinuria with normal renal function for age. Renal pathology is limited to glycosphingolipid deposition in podocytes, which is presumably responsible for their proteinuria. They generally do not develop renal failure.</p>
            <p><bold>Renal variant.</bold> Renal variants were identified among individuals of Japanese ancestry on chronic hemodialysis in whom ESRD had been misdiagnosed as chronic glomerulonephritis [<xref ref-type="bibr" rid="fabry.REF.nakao.2003.801">Nakao et al 2003</xref>]. Of note, five of the six individuals did not have angiokeratoma, acroparesthesia, hypohidrosis, or corneal opacities, but did have moderate to severe left ventricular hypertrophy. These observations indicated that the early symptoms of classic Fabry disease may not occur in individuals with the renal variant who develop renal insufficiency, and that the renal variant may be underdiagnosed. Therefore, it is appropriate to test individuals on renal dialysis and/or undergoing renal transplantation without a confirmed etiology of renal disease for Fabry disease.</p>
          </sec>
        </sec>
        <sec id="fabry.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Efforts to establish genotype-phenotype correlations have been limited because most families with Fabry disease have a private pathogenic variant, and there is significant phenotypic variability even among individuals with the same pathogenic variant.</p>
          <list list-type="bullet">
            <list-item>
              <p>Males with the classic phenotype have a variety of <italic toggle="yes">GLA</italic> variants, including large and small gene rearrangements, splicing defects, and missense or nonsense variants [<xref ref-type="bibr" rid="fabry.REF.desnick.2001">Desnick et al 2001</xref>, <xref ref-type="bibr" rid="fabry.REF.sch_fer.2005.412">Sch&#x000e4;fer et al 2005</xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.hgmd.cf.ac.uk/ac/index.php">Human Gene Mutation Database</ext-link>].</p>
            </list-item>
            <list-item>
              <p>Individuals with later-onset atypical variants (renal, cardiac, or cerebrovascular disease) have missense or splicing variants that express residual &#x003b1;-Gal A enzyme activity [<xref ref-type="bibr" rid="fabry.REF.rolfs.2005.1794">Rolfs et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p>A number of pathogenic variants including <xref ref-type="table" rid="fabry.T.selected_gla_variants">p.Arg112His</xref>, <xref ref-type="table" rid="fabry.T.selected_gla_variants">p.Arg301Gln</xref>, and <xref ref-type="table" rid="fabry.T.selected_gla_variants">p.Gly328Arg</xref> have been identified in individuals with both the classic phenotype and the cardiac variant phenotype, suggesting that other modifying factors are involved in disease expression [<xref ref-type="bibr" rid="fabry.REF.ashtonprolla.2000.227">Ashton-Prolla et al 2000</xref>].</p>
            </list-item>
            <list-item>
              <p>An analysis of the Fabry Outcome Survey (FOS) showed that disease manifestations in individuals with the <xref ref-type="table" rid="fabry.T.selected_gla_variants">p.Asn215Ser</xref> pathogenic variant were less severe than in age-matched individuals with Fabry disease caused by pathogenic variants associated with classic disease [<xref ref-type="bibr" rid="fabry.REF.schaefer.2005.87">Schaefer et al 2005</xref>].</p>
            </list-item>
            <list-item>
              <p>Newborn screening in Taiwan has revealed a high prevalence (~1:1600 males) of individuals with the IVS4+919G&#x0003e;A pathogenic variant where older family members with late-onset cardiac features have been found [<xref ref-type="bibr" rid="fabry.REF.lin.2009.450">Lin et al 2009</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="fabry.Prevalence">
          <title>Prevalence</title>
          <p>The incidence of Fabry disease is estimated at 1:50,000 to 1:117,000 males [<xref ref-type="bibr" rid="fabry.REF.meikle.1999.249">Meikle et al 1999</xref>, <xref ref-type="bibr" rid="fabry.REF.desnick.2001">Desnick et al 2001</xref>].</p>
          <p>Recent studies suggest that milder forms of the disease that present later in life and primarily affect the cardiovascular, cerebrovascular, or renal system may be more common and may be underdiagnosed.</p>
          <p>A newborn screening study from Italy shows an incidence as high as 1:3,100, with an 11:1 ratio of persons with the later-onset/classic phenotypes [<xref ref-type="bibr" rid="fabry.REF.spada.2006.31">Spada et al 2006</xref>]. The incidence of Fabry disease among nearly 35,000 neonates screened in Austria is 1:3859 [<xref ref-type="bibr" rid="fabry.REF.mechtler.2012.335">Mechtler et al 2012</xref>].</p>
          <p>In a study of the Taiwan Chinese population an unexpected high prevalence of the cardiac-variant Fabry-causing pathogenic variant c.640-801G&#x0003e;A (also known as IVS4+919G&#x0003e;A and c.639+919G&#x0003e;A) was found among newborns (~1:1600 males) as well as individuals with idiopathic hypertrophic cardiomyopathy [<xref ref-type="bibr" rid="fabry.REF.lin.2009.450">Lin et al 2009</xref>].</p>
          <p>Fabry disease is found among all ethnic, racial, and demographic groups.</p>
        </sec>
      </sec>
      <sec id="fabry.Genetically_Related_Allelic_Disord">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> have been associated with pathogenic variants in <italic toggle="yes">GLA</italic>.</p>
      </sec>
      <sec id="fabry.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The pain of Fabry disease may be associated with a low-grade fever and an elevated erythrocyte sedimentation rate; these symptoms have frequently led to the misdiagnosis of rheumatic fever, neurosis, or <related-object link-type="booklink" source-id="gene" document-id="etha" document-type="chapter">erythromelalgia</related-object>.</p>
        <p>Symptoms in individuals with Fabry disease are similar to those of other disorders including rheumatoid arthritis, juvenile arthritis, rheumatic fever, systemic lupus erythematosus (SLE), "growing pains," petechiae, Raynaud syndrome, early-onset stroke [<xref ref-type="bibr" rid="fabry.REF.cabrerasalazar.2005.102">Cabrera-Salazar et al 2005</xref>, <xref ref-type="bibr" rid="fabry.REF.rolfs.2005.1794">Rolfs et al 2005</xref>] and multiple sclerosis [<xref ref-type="bibr" rid="fabry.REF.callegaro.2006.27">Callegaro &#x00026; Kaimen-Maciel 2006</xref>].</p>
        <p>Males with Fabry disease may be unrecognized in cardiac clinics, where they are diagnosed with <related-object link-type="booklink" source-id="gene" document-id="hyper-card" document-type="chapter">hypertrophic cardiomyopathy</related-object>, and in nephrology clinics, where they are diagnosed with end-stage renal disease [<xref ref-type="bibr" rid="fabry.REF.bekri.2005.c33">Bekri et al 2005</xref>, <xref ref-type="bibr" rid="fabry.REF.ichinose.2005.228">Ichinose et al 2005</xref>, <xref ref-type="bibr" rid="fabry.REF.tanaka.2005.281">Tanaka et al 2005</xref>].</p>
        <p>Two studies have indicated that several individuals with <related-object link-type="booklink" source-id="gene" document-id="fmf" document-type="chapter">familial Mediterranean fever</related-object>, which can also cause pain and renal involvement, have been misdiagnosed as having Fabry disease [<xref ref-type="bibr" rid="fabry.REF.lidove.2012.571">Lidove et al 2012</xref>, <xref ref-type="bibr" rid="fabry.REF.zizzo.2013.576">Zizzo et al 2013</xref>].</p>
        <p>Differential diagnosis of the cutaneous lesions must exclude the angiokeratoma of Fordyce spots, angiokeratoma of Mibelli, and angiokeratoma circumscriptum, none of which has the typical histologic or ultrastructural lysosomal storage pathology of the Fabry lesion:</p>
        <list list-type="bullet">
          <list-item>
            <p>Angiokeratoma of Fordyce is characterized by spots similar in appearance to those of Fabry disease but limited to the scrotum and usually appearing after age 30 years.</p>
          </list-item>
          <list-item>
            <p>Angiokeratoma of Mibelli is characterized by warty lesions on the extensor surfaces of extremities in young adults and associated with erythematous subcutaneous swellings (chilblains).</p>
          </list-item>
          <list-item>
            <p>Angiokeratoma circumscriptum or naeviforme can occur anywhere on the body, is clinically and histologically similar to angiokeratoma of Fordyce, and is not associated with chilblains.</p>
          </list-item>
        </list>
        <p>Angiokeratomas, in clinical appearance and distribution reportedly similar to or indistinguishable from the cutaneous lesions seen in individuals with Fabry disease, have been described in individuals with other lysosomal storage diseases, including fucosidosis, sialidosis (&#x003b1;-neuraminidase deficiency with or without &#x003b2;-galactosidase deficiency), adult-type &#x003b2;-galactosidase deficiency, aspartylglucosaminuria, adult-onset &#x003b1;-galactosidase B deficiency, &#x003b2;-mannosidase deficiency, and a lysosomal disorder with intellectual disability and some features of the mucopolysaccharidoses [<xref ref-type="bibr" rid="fabry.REF.desnick.2001">Desnick et al 2001</xref>].</p>
      </sec>
      <sec id="fabry.Management">
        <title>Management</title>
        <sec id="fabry.Evaluations_Following_Initial_Diag">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with Fabry disease, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Careful history for evidence of acroparesthesia, sweating abnormalities (i.e., hypohidrosis), or other manifestations of the disorder</p>
            </list-item>
            <list-item>
              <p>Renal function studies, including BUN, creatinine, and urinalysis</p>
            </list-item>
            <list-item>
              <p>Cardiac evaluation, including echocardiography</p>
            </list-item>
            <list-item>
              <p>Examination of the skin for angiokeratomas</p>
            </list-item>
            <list-item>
              <p>Formal audiology assessment</p>
            </list-item>
            <list-item>
              <p>Ophthalmologic evaluation</p>
            </list-item>
            <list-item>
              <p>Neurologic assessment</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="fabry.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>
            <bold>Acroparesthesia</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Diphenylhydantoin.</bold> The severe pain of such episodes in affected males and heterozygous females often responds to low-maintenance doses of diphenylhydantoin by reducing the frequency and severity of the periodic crises of excruciating pain and constant discomfort. A potential side effect of diphenylhydantoin is gingival hypertrophy.</p>
            </list-item>
            <list-item>
              <p><bold>Carbamazepine</bold> has similar effects. The combination of the two drugs may also significantly reduce the frequency and severity of the pain. Dose-related autonomic complications with carbamazepine include urinary retention, nausea, vomiting, and ileus.</p>
            </list-item>
            <list-item>
              <p><bold>Gabapentin</bold> has been demonstrated to improve pain [<xref ref-type="bibr" rid="fabry.REF.ries.2003.413">Ries et al 2003</xref>].</p>
            </list-item>
          </list>
          <p><bold>Renal disease.</bold> Renal insufficiency is the most frequent and serious late complication in males with the classic phenotype. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) should be used in those with evidence of renal involvement, especially to reduce proteinuria [<xref ref-type="bibr" rid="fabry.REF.waldek.2014.72">Waldek &#x00026; Feriozzi 2014</xref>, <xref ref-type="bibr" rid="fabry.REF.warnock.2015.860">Warnock et al 2015</xref>].</p>
          <p>Chronic hemodialysis and/or renal transplantation have become lifesaving procedures. The engrafted kidney remains histologically free of glycosphingolipid deposition because the normal alpha-galactosidase A (&#x003b1;-Gal A) enzyme activity in the allograft catabolizes endogenous renal glycosphingolipid substrates. Therefore, successful renal transplantation corrects renal function.</p>
          <p>Reviews of the registries of the European Renal Association-European Dialysis and Transplantation Association and the United States Renal Data System support excellent outcomes for renal transplantation in individuals with Fabry disease. For example, during the ten-year period from 1988 to 1998, 93 individuals who underwent renal transplantation were reported to the US registry. Compared to a matched control group, recipients with Fabry disease had equivalent five-year life survival (82% vs 83%) and graft survival (67% vs 75%), respectively.</p>
          <p>Note: (1) Immune function in males with Fabry disease is similar to that in other individuals with uremia, obviating any immunologic contraindication to transplantation in this disease. Autoimmune conditions have, however, been reported to occur at an increased frequency in individuals with Fabry disease [<xref ref-type="bibr" rid="fabry.REF.martinez.2007.365">Martinez et al 2007</xref>]. (2) Transplantation of kidneys from female heterozygotes should be avoided, as the organs may already contain significant substrate deposition; all related potential donors must be evaluated to exclude affected males and heterozygous females.</p>
        </sec>
        <sec id="fabry.Prevention_of_Primary_Manifestatio">
          <title>Prevention of Primary Manifestations</title>
          <p><bold>Enzyme replacement therapy (ERT).</bold> The two ERTs using recombinant or gene-activated human &#x003b1;-Gal A enzyme that have been evaluated in clinical trials are Fabrazyme<sup>&#x000ae;</sup> (agalsidase beta 1 mg/kg every 2 weeks) and Replagal&#x02122; (agalsidase alfa 0.2 mg/kg every 2 weeks). Both were approved in 2001 by the European Agency for Evaluation of Medical Products; only Fabrazyme<sup>&#x000ae;</sup> was approved by the FDA for use in the United States.</p>
          <p>The following is a summary of some of the clinical trials for each drug:</p>
          <list list-type="bullet">
            <list-item>
              <p>Single-center double-blind placebo-controlled studies of agalsidase alfa have shown a beneficial effect of ERT on neuropathic pain [<xref ref-type="bibr" rid="fabry.REF.schiffmann.2001.2743">Schiffmann et al 2001</xref>] and left ventricular hypertrophy [<xref ref-type="bibr" rid="fabry.REF.hughes.2008.153">Hughes et al 2008</xref>]. Data from the Fabry Outcome Survey (FOS) suggest that ERT with agalsidase alfa improves pain and quality of life, reduces the natural rate of decline of renal and cardiac function in males and females with Fabry disease [<xref ref-type="bibr" rid="fabry.REF.mehta.2009.548">Mehta et al 2009</xref>] and may improve life expectancy [<xref ref-type="bibr" rid="fabry.REF.beck.2015.21">Beck et al 2015</xref>]. The enzyme is safe in children [<xref ref-type="bibr" rid="fabry.REF.ramaswami.2006.86">Ramaswami et al 2006</xref>]. In persons with advanced renal disease, weekly administration of 0.2 mg/kg agalsidase alfa may be associated with a slower decline in renal function [<xref ref-type="bibr" rid="fabry.REF.schiffmann.2007.1576">Schiffmann et al 2007</xref>, <xref ref-type="bibr" rid="fabry.REF.schiffmann.2015.1129">Schiffmann et al 2015</xref>].</p>
            </list-item>
            <list-item>
              <p>A double-blind, randomized, placebo-controlled study of agalsidase beta demonstrated increased clearance of globotriaosylceramide (GL-3) from the endothelial cells of the kidney, heart, and skin among treated subjects [<xref ref-type="bibr" rid="fabry.REF.eng.2001.9">Eng et al 2001</xref>].</p>
            </list-item>
            <list-item>
              <p>A Phase IV extension study showed that the risk of major clinical events (a combination of death, myocardial infarction, stroke, development of ESRD, or a 33% increase in serum creatinine concentration) was reduced by 53% with agalsidase beta treatment after adjustment for baseline proteinuria (P=0.06) [<xref ref-type="bibr" rid="fabry.REF.banikazemi.2007.77">Banikazemi et al 2007</xref>]. In a ten-year follow up of these individuals, with additional data from the Fabry Registry, <xref ref-type="bibr" rid="fabry.REF.germain.2015.353">Germain et al [2015]</xref> reported that 49 of 52 were alive and 42/52 (81%) did not experience any severe clinical events during the ten-year treatment interval. Disease progression was most likely to be observed in those individuals who initiated treatment after age 40 years and/or had advanced renal disease at baseline. A study of cardiac outcomes from the Fabry Registry of 115 males treated with agalsidase beta for at least two years reports that treated individuals fared better than 48 untreated males. Left ventricular mass fell at a slope of -3.6 g/year in 31 males aged 18-30 years but rose by 9.5 g/year in 15 males who were not treated [<xref ref-type="bibr" rid="fabry.REF.germain.2013.958">Germain et al 2013</xref>].</p>
            </list-item>
            <list-item>
              <p>The largest comparative study is the Canadian Fabry Disease initiative. <xref ref-type="bibr" rid="fabry.REF.sirrs.2014.499">Sirrs et al [2014]</xref> have reported five-year follow-up data on 362 subjects for a composite endpoint (death, neurologic or cardiovascular events, development of ESRD, or sustained increase in serum creatinine of 50% from baseline). Ninety-two of 178 individuals treated with ERT were randomly allocated to either agalsidase alfa or agalsidase beta. No differences were found with regard to the clinical efficacy of the two medications, and individuals who switched from agalsidase beta to agalsidase alfa during the time of Fabrazyme<sup>&#x000ae;</sup> shortage were stable. In comparison with the placebo group in the Banikazemi study individuals treated with ERT had a significant reduction in clinical events, which occurred at an older age. The eight-year follow-up data continued to suggest that the two medications are equivalent at their standard doses [M West, personal communication].</p>
            </list-item>
            <list-item>
              <p>Antibody formation has been reported with both agalsidase alfa and agalsidase beta in males, but not females [<xref ref-type="bibr" rid="fabry.REF.linthorst.2005.201">Linthorst et al 2005</xref>, <xref ref-type="bibr" rid="fabry.REF.wilcox.2012.443">Wilcox et al 2012</xref>]. <xref ref-type="bibr" rid="fabry.REF.lenders.2015.1009">Lenders et al [2015]</xref> reported that 40% of 68 males with Fabry disease on ERT have evidence of serum-mediated inhibition of agalsidase activity. They further reported that inhibition-positive individuals have worse clinical outcomes and higher levels of lyso-Gb3 than inhibition-negative individuals. There appeared to be no difference between agalsidase alfa and beta with regard to the development of serum inhibitors. The impact of antibody formation on the overall efficacy of treatment is currently unknown.</p>
            </list-item>
            <list-item>
              <p>During 2009-2012, a shortage of agalsidase beta resulted in the substitution of agalsidase alfa for agalsidase beta in several cohorts of affected individuals. Reports thus far have not indicated any significant difference in clinical parameters as a result of this transition [<xref ref-type="bibr" rid="fabry.REF.smid.2011.69">Smid et al 2011</xref>, <xref ref-type="bibr" rid="fabry.REF.tsuboi.2012.779">Tsuboi &#x00026; Yamamoto 2012</xref>, <xref ref-type="bibr" rid="fabry.REF.pisani.2013.41">Pisani et al 2013</xref>, <xref ref-type="bibr" rid="fabry.REF.gokeralpan.2016.95">Goker-Alpan et al 2016</xref>].</p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="fabry.REF.lubanda.2009.256">Lubanda et al [2009]</xref> have shown in a small study of 21 individuals that those who have been &#x02018;stabilized&#x02019; with agalsidase beta at 1 g/kg can thereafter be safely treated with a maintenance dose of 0.3 g/kg every other week. A study of lower-dose agalsidase beta has been conducted in children (FIELD study [<xref ref-type="bibr" rid="fabry.REF.wijburg.2015.e0124987">Wijburg et al 2015</xref>]); it will be interesting to observe if lower doses of agalsidase beta are equally efficacious in children.</p>
            </list-item>
          </list>
          <p>There is an emerging consensus that ERT has, at best, a limited impact on the long-term outcome of Fabry disease. Studies of consecutive affected persons from individual centers suggest that cardiac, renal, and cerebrovascular outcomes are comparable among treated and untreated cohorts [<xref ref-type="bibr" rid="fabry.REF.rombach.2013.29">Rombach et al 2013</xref>, <xref ref-type="bibr" rid="fabry.REF.weidemann.2013.331">Weidemann et al 2013</xref>]. A recent Cochrane review has also highlighted the generally poor quality of evidence in favor of ERT for Fabry disease.</p>
          <p>Despite these emerging data, a panel of physician experts have recommended that ERT be initiated as early as possible in all males with Fabry disease, including children and those with ESRD undergoing dialysis and renal transplantation, and in heterozygous females with significant disease [<xref ref-type="bibr" rid="fabry.REF.desnick.2003.338">Desnick et al 2003</xref>, <xref ref-type="bibr" rid="fabry.REF.eng.2006.539">Eng et al 2006</xref>] because all are at high risk for cardiac, cerebrovascular, and neurologic complications including transient ischemic attacks and strokes. The treatment initiation guidelines from a group of European physicians are generally more conservative [<xref ref-type="bibr" rid="fabry.REF.biegstraaten.2015.36">Biegstraaten et al 2015</xref>]. They emphasize the need to start ERT before the advent of irreversible complications and suggest that initiation of ERT after irreversible organ damage has occurred is to be avoided. ERT should be discontinued if it is making no impact on organ function in an individual; and compliance should be closely monitored.</p>
        </sec>
        <sec id="fabry.Prevention_of_Secondary_Complicati">
          <title>Prevention of Secondary Complications</title>
          <p>The prophylaxis for renovascular disease, ischemic heart disease, and cerebrovascular disease in persons with Fabry disease is the same as for the general population.</p>
          <list list-type="bullet">
            <list-item>
              <p>Proteinuria/microalbuminuria should be minimized with ACE inhibitors/ARBs [<xref ref-type="bibr" rid="fabry.REF.tahir.2007.2609">Tahir et al 2007</xref>]; blood pressure control optimized; and cholesterol normalized [<xref ref-type="bibr" rid="fabry.REF.waldek.2014.72">Waldek &#x00026; Feriozzi 2014</xref>].</p>
            </list-item>
            <list-item>
              <p>Aspirin and other anti-platelet agents such as clopidogrel may be recommended for the prophylaxis of stroke.</p>
            </list-item>
            <list-item>
              <p>Although evidence as to the effect on long-term outcomes is lacking, use of aspirin and lipid-lowering agents and optimal blood pressure control are recommended in persons with symptoms of cardiac ischemia [<xref ref-type="bibr" rid="fabry.REF.eng.2006.539">Eng et al 2006</xref>].</p>
            </list-item>
          </list>
          <p>The role of ERT in the long-term prophylaxis of renal, cardiac, and CNS manifestations is unproven; however, on the basis of stabilization of organ function in persons with more advanced disease, some have suggested the initiation of ERT in early disease stages: at first sign of disease manifestations in boys; at age 12-13 years in asymptomatic boys; and at the time of diagnosis in adult males [<xref ref-type="bibr" rid="fabry.REF.eng.2006.539">Eng et al 2006</xref>]. Studies indicate that late initiation of therapy when renal or cardiac manifestations are significant is associated with less effect than initiation earlier in the disease course [<xref ref-type="bibr" rid="fabry.REF.germain.2015.353">Germain et al 2015</xref>, <xref ref-type="bibr" rid="fabry.REF.ortiz.2016.495">Ortiz et al 2016</xref>].</p>
        </sec>
        <sec id="fabry.Surveillance">
          <title>Surveillance</title>
          <p>The following are appropriate:</p>
          <list list-type="bullet">
            <list-item>
              <p>Annual or more frequent renal function studies</p>
            </list-item>
            <list-item>
              <p>Annual cardiology evaluation</p>
            </list-item>
            <list-item>
              <p>Annual audiology evaluation</p>
            </list-item>
            <list-item>
              <p>Biennial brain MRI/MRA</p>
            </list-item>
          </list>
        </sec>
        <sec id="fabry.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>The obstructive lung disease, which has been documented in older hemizygous males and heterozygous females, is more severe in smokers; therefore, affected individuals should be discouraged from smoking.</p>
          <p>Amiodarone has been reported to induce cellular and biochemical changes resulting in a phenocopy in particular of the keratopathy of Fabry disease [<xref ref-type="bibr" rid="fabry.REF.whitley.1983.2177">Whitley et al 1983</xref>]. Given potential effects on cellular levels of &#x003b1;-Gal A enzyme activity, it has been contraindicated in persons with Fabry disease. However, little evidence of a detrimental effect in this specific group exists and the relative benefit in individuals with cardiac arrhythmia should be considered.</p>
        </sec>
        <sec id="fabry.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate apparently asymptomatic older and younger at-risk male and female relatives of an affected individual in order to identify as early as possible those who would benefit from initiation of treatment (ERT) and preventive measures.</p>
          <p>Evaluations can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing if the pathogenic variant in the family is known.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant in the family is not known:</p>
              <list list-type="bullet">
                <list-item>
                  <p><bold>Males.</bold> Measure &#x003b1;-Gal A enzyme activity.</p>
                </list-item>
                <list-item>
                  <p><bold>Females.</bold> Measurement of &#x003b1;-Gal A enzyme activity is unreliable in females although demonstration of decreased &#x003b1;-Gal A enzyme activity is diagnostic of the heterozygous state. Ophthalmologic examination for the characteristic whorl-like corneal opacities by slit-lamp microscopy can be considered if enzyme analysis is uninformative. However, only 80%-90% of heterozygous females have the corneal lesions.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="fabry.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="fabry.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p><bold>Gene replacement therapy</bold> has been investigated in the mouse model of Fabry disease [<xref ref-type="bibr" rid="fabry.REF.ziegler.1999.1667">Ziegler et al 1999</xref>, <xref ref-type="bibr" rid="fabry.REF.ziegler.2002.935">Ziegler et al 2002</xref>, <xref ref-type="bibr" rid="fabry.REF.ziegler.2004.231">Ziegler et al 2004</xref>]. A trial of gene therapy via autologous stem cell transplantation is currently in progress in Canada.</p>
          <p><bold>Chaperone therapy,</bold> a novel approach, uses small molecules designed to enhance the residual enzyme activity by protecting the mutated enzyme from misfolding and degradation in the cell [<xref ref-type="bibr" rid="fabry.REF.desnick.2002.954">Desnick &#x00026; Schuchman 2002</xref>]. A report of chaperone therapy in a male with the cardiac variant demonstrated the "proof of concept" for this therapeutic strategy for Fabry disease [<xref ref-type="bibr" rid="fabry.REF.frustaci.2001.25">Frustaci et al 2001</xref>].</p>
          <p>Phase I trials have demonstrated elevation of plasma &#x003b1;-Gal A levels in healthy volunteers [<xref ref-type="bibr" rid="fabry.REF.fan.1999.112">Fan et al 1999</xref>, <xref ref-type="bibr" rid="fabry.REF.ishii.2004.250">Ishii et al 2004</xref>]. Phase III trials are now in progress in males and females with Fabry disease with a pharmacologic chaperone (1-deoxygalactonojirimycin; DGJ; Migalastat Amicus Therapeutics, NJ, USA). DGJ has been demonstrated to enhance trafficking of mutated &#x003b1;-Gal A to lysosomes of fibroblasts derived from persons with Fabry disease and to increase enzyme activity while reducing GL-3 substrate in tissues of a transgenic/knockout animal model of Fabry disease. In 2016 Migalastat received marketing approval in the European Union.</p>
          <p><bold>Alternative enzyme therapy.</bold> A PEGylated version of recombinant &#x003b1;-Gal A with a longer circulating half-life is currently in a Phase II trial.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
        <sec id="fabry.Other">
          <title>Other</title>
          <p>Substrate reduction therapy for Fabry disease has a biochemical rationale. Clinical trials of substrate reduction therapy will be commencing soon.</p>
        </sec>
      </sec>
      <sec id="fabry.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="fabry.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Fabry disease is inherited in an X-linked manner.</p>
        </sec>
        <sec id="fabry.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of an affected male proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The father of an affected male will not have the disorder nor will he be hemizygous for the <italic toggle="yes">GLA</italic> pathogenic variant; therefore, he does not require further evaluation/testing.</p>
            </list-item>
            <list-item>
              <p>In a family with more than one affected individual, the mother of an affected male individual is an obligate heterozygote (carrier).</p>
              <p>Note: If a woman has more than one affected child and no other affected relatives and the <italic toggle="yes">GLA</italic> pathogenic variant cannot be detected in her leukocyte DNA, maternal germline mosaicism should be considered as a possible explanation.</p>
            </list-item>
            <list-item>
              <p>If only one individual in the family is affected, the mother of the affected male is likely heterozygous for the <italic toggle="yes">GLA</italic> pathogenic variant. Rarely, an affected male may have a <italic toggle="yes">de novo</italic> pathogenic variant, in which case the mother is not a carrier.</p>
            </list-item>
          </list>
          <p><bold>Sibs of an affected male proband.</bold> The risk to sibs depends on the genetic status of the mother:</p>
          <list list-type="bullet">
            <list-item>
              <p>If the mother of the proband has a pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be will be heterozygotes and may be symptomatic. See Clinical Description, <xref ref-type="sec" rid="fabry.Heterozygous_Carrier_Females">Heterozygous (Carrier) Females</xref>.</p>
            </list-item>
            <list-item>
              <p>If the proband represents a simplex case (i.e., a single occurrence in a family) and if the <italic toggle="yes">GLA</italic> pathogenic variant cannot be detected in the leukocyte DNA of the mother, the risk to sibs is low but greater than that of the general population because of the theoretic possibility of maternal germline mosaicism.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a (symptomatic or asymptomatic) heterozygous female</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>If the father of the proband has a <italic toggle="yes">GLA</italic> pathogenic variant, he will transmit it to all his daughters and none of his sons.</p>
            </list-item>
            <list-item>
              <p>If the mother of the proband has a <italic toggle="yes">GLA</italic> pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be heterozygotes (carriers) and may be symptomatic. See <xref ref-type="sec" rid="fabry.Heterozygous_Carrier_Females">Heterozygous (Carrier) Females</xref>.</p>
            </list-item>
            <list-item>
              <p>Paternal germline mosaicism has been demonstrated in this condition [<xref ref-type="bibr" rid="fabry.REF.dobrovoln_.2005.84">Dobrovoln&#x000fd; et al 2005</xref>]. Thus, even if the <italic toggle="yes">GLA</italic> pathogenic variant has not been identified in paternal leukocyte DNA, female sibs of a heterozygous female may still be at increased risk of inheriting the pathogenic variant.</p>
            </list-item>
          </list>
          <p><bold>Offspring of an affected male.</bold> Affected males transmit the <italic toggle="yes">GLA</italic> pathogenic variant to:</p>
          <list list-type="bullet">
            <list-item>
              <p>All of their daughters who will be heterozygotes and may be symptomatic. See <xref ref-type="sec" rid="fabry.Heterozygous_Carrier_Females">Heterozygous (Carrier) Females</xref>.</p>
            </list-item>
            <list-item>
              <p>None of their sons.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a (symptomatic or asymptomatic) heterozygous female.</bold> Women with a <italic toggle="yes">GLA</italic> pathogenic variant have a 50% chance of transmitting the pathogenic variant to each child:</p>
          <list list-type="bullet">
            <list-item>
              <p>Males who inherit the pathogenic variant will be affected.</p>
            </list-item>
            <list-item>
              <p>Females who inherit the pathogenic variant will be heterozygotes and may be symptomatic. See <xref ref-type="sec" rid="fabry.Heterozygous_Carrier_Females">Heterozygous (Carrier) Females</xref>.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> The proband's maternal aunts may be at risk of being heterozygotes and the aunts' offspring, depending on their gender, may be at risk of being heterozygotes and/or of being affected. At-risk females should be offered clinical examination, genetic counseling, and molecular genetic testing.</p>
        </sec>
        <sec id="fabry.Heterozygote_Carrier_Detection">
          <title>Heterozygote (Carrier) Detection</title>
          <p><bold>Molecular genetic testing</bold> of at-risk female relatives to determine their genetic status is most informative if the <italic toggle="yes">GLA</italic> pathogenic variant has been identified in the proband.</p>
          <p><bold>Measurement of alpha-galactosidase A (&#x003b1;-Gal A) enzyme activity</bold> is unreliable for carrier detection. Although demonstration of decreased &#x003b1;-Gal A activity in a female is diagnostic of the heterozygous state, some heterozygotes have &#x003b1;-Gal A activity in the normal range.</p>
          <p><bold>Ophthalmologic examination</bold> for the characteristic whorl-like corneal opacities by slit-lamp microscopy can be considered if enzyme analysis is uninformative and the specific <italic toggle="yes">GLA</italic> pathogenic variant in the family has not been identified by molecular genetic testing. However, only 80%-90% of heterozygous females have the corneal lesions.</p>
        </sec>
        <sec id="fabry.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>Fabry disease practice guidelines are available. See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://link.springer.com/article/10.1007%2Fs10897-013-9613-3">Fabry Disease Practice Guidelines: Recommendations of the National Society of Genetic Counselors</ext-link> [<xref ref-type="bibr" rid="fabry.REF.laney.2013">Laney et al 2013</xref>].</p>
          <p>See Management, <xref ref-type="sec" rid="fabry.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of genetic status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="fabry.Prenatal_Testing_and_Preimplantati">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>Molecular genetic testing.</bold> Once the <italic toggle="yes">GLA</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible.</p>
          <p><bold>Biochemical testing.</bold> If the karyotype is 46,XY, &#x003b1;-Gal A enzyme activity can be measured in fetal cells. (If the <italic toggle="yes">GLA</italic> pathogenic variant has been identified in an affected family member, a biochemical diagnosis can be confirmed by molecular genetic testing of fetal DNA.)</p>
        </sec>
      </sec>
      <sec id="fabry.Resources">
        <title>Resources</title>
      </sec>
      <sec id="fabry.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">GLA</italic> spans approximately 13 kb of gDNA and contains seven exons; the cDNA is 1290 bases and encodes a polypeptide of 429 amino acids including a 31-amino acid signal peptide. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="fabry" object-id="fabry.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Benign variants.</bold> The variant p.Asp313Tyr, a common exon 6 variant with decreased activity in vitro and reduced activity at neutral pH resulting in low plasma alpha-galactosidase A (&#x003b1;-Gal A) activity, has been identified in 0.45% of normal individuals (n = 800 alleles). Expression of p.Asp313Tyr in COS-7 cells resulted in approximately 60% of wild-type enzymatic activity and showed normal lysosomal localization [<xref ref-type="bibr" rid="fabry.REF.froissart.2003.307">Froissart et al 2003</xref>, <xref ref-type="bibr" rid="fabry.REF.yasuda.2003.162">Yasuda et al 2003</xref>]. Thus, p.Asp313Tyr is a variant that does not cause Fabry disease.</p>
        <p><bold>Pathogenic variants.</bold> More than 800 <italic toggle="yes">GLA</italic> pathogenic variants have been identified, and most are family specific, occurring only in single pedigrees. Affected males with frameshift and nonsense variants typically present with classic Fabry disease; males with missense pathogenic variants can present with either classic or atypical phenotypes [<xref ref-type="bibr" rid="fabry.REF.pan.2016.e0161330">Pan et al 2016</xref>].</p>
        <p><italic toggle="yes">GLA</italic> pathogenic variants that result in residual &#x003b1;-gal A activity of about 20% have been identified in individuals with atypical variants of Fabry disease. The clinical manifestations of atypical cases are not specific to Fabry disease (e.g., stroke, cardiomyopathy); therefore, the pathogenicity of some variants is unclear [<xref ref-type="bibr" rid="fabry.REF.lukas.2016.43">Lukas et al 2016</xref>]. A number of variants including p.Ile91Thr, p.Arg112His, p.Phe113Leu, p.Asn215Ser, p.Met296Ile, p.Arg301Gln, and p.Gly328Arg are recurrent and associated with late-onset cardiac disease [<xref ref-type="bibr" rid="fabry.REF.patel.2015.961">Patel et al 2015</xref>]. Most individuals with the IVS4+919G&#x0003e;A pathogenic variant were not diagnosed until newborn screening identified this variant in their grandsons [<xref ref-type="bibr" rid="fabry.REF.liu.2015.107">Liu et al 2015</xref>].</p>
        <p>The pathogenicity of some <italic toggle="yes">GLA</italic> variants is disputed. The p.Arg118Cys variant has been recurrently described in large Fabry disease screening studies of high-risk individuals; however, this variant does not always segregate with Fabry disease in a Mendelian fashion, and could be a modulator of cerebrovascular disease risk [<xref ref-type="bibr" rid="fabry.REF.ferreira.2015.248">Ferreira et al 2015</xref>]. The p.Ala143Thr variant has been associated with renal failure, stroke, and left ventricular hypertrophy which could potentially be the result of selection bias, as most individuals were detected in screening studies [<xref ref-type="bibr" rid="fabry.REF.terryn.2013.101">Terryn et al 2013</xref>].</p>
        <table-wrap id="fabry.T.selected_gla_variants" orientation="portrait" position="anchor">
          <label>Table 3. </label>
          <caption>
            <p>Selected <italic toggle="yes">GLA</italic> Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_fabry.T.selected_gla_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                <th id="hd_h_fabry.T.selected_gla_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_fabry.T.selected_gla_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_fabry.T.selected_gla_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Benign</bold>
                </td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.937G&#x0003e;T</td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asp313Tyr</td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_4" rowspan="12" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000169.2">NM_000169.2</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000160.1">NP_000160.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Uncertain</bold>
                </td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.352C&#x0003e;T</td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg118Cys</td>
              </tr>
              <tr>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.427G&#x0003e;A</td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala143Thr</td>
              </tr>
              <tr>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_1" rowspan="9" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Pathogenic</bold>
                </td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.272T&#x0003e;C</td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ile91Thr</td>
              </tr>
              <tr>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.335G&#x0003e;A</td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg112His&#x000a0;<sup>1</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.337T&#x0003e;C</td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Phe113Leu</td>
              </tr>
              <tr>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.427G&#x0003e;C</td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala143Pro</td>
              </tr>
              <tr>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.640-801G&#x0003e;A (IVS4+919G&#x0003e;A; c.639+919G&#x0003e;A)</td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">--</td>
              </tr>
              <tr>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.644A&#x0003e;G</td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asn215Ser</td>
              </tr>
              <tr>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.888G&#x0003e;A</td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Met296Ile</td>
              </tr>
              <tr>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.902G&#x0003e;A</td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg301Gln&#x000a0;<sup>1</sup></td>
              </tr>
              <tr>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.982G&#x0003e;A</td>
                <td headers="hd_h_fabry.T.selected_gla_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly328Arg&#x000a0;<sup>1</sup></td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="fabry.TF.3.1">
              <label>1. </label>
              <p>See <xref ref-type="sec" rid="fabry.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> Alpha-galactosidase A (&#x003b1;-Gal A) is a lysosomal exoglycohydrolase. The mature &#x003b1;-Gal A enzyme polypeptide is 398 amino acids and contains three functional N-glycosylation sites. The active enzyme is a homodimer of approximately 101 kd.</p>
        <p><bold>Abnormal gene product.</bold>
<italic toggle="yes">GLA</italic> pathogenic variants result in mRNA instability and/or severely truncated &#x003b1;-Gal A or an enzyme with markedly decreased activity.</p>
      </sec>
      <sec id="fabry.References">
        <title>References</title>
        <sec id="fabry.Published_GuidelinesConsensus_Stat">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="fabry.Published_GuidelinesConsensus_Stat.reflist0">
            <ref id="fabry.REF.bennett.2002">
              <mixed-citation publication-type="web">Bennett RL, Hart KA, O Rourke E, Barranger JA, Johnson J, MacDermot KD, Pastores GM, Steiner RD, Thadhani R. Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors (pdf). Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.springerlink.com/content/pd2ejhrnrwtxac20/fulltext.pdf">online</ext-link>. 2002. Accessed 3-22-17.</mixed-citation>
            </ref>
            <ref id="fabry.REF.gal.2011">
              <mixed-citation publication-type="web">Gal A, Hughes DA, Winchester B. Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063537/">online</ext-link>. 2011. Accessed 3-22-17.</mixed-citation>
            </ref>
            <ref id="fabry.REF.laney.2013">
              <mixed-citation publication-type="web">Laney DA, Bennett RL, Clarke V, Fox A, Hopkin RJ, Johnson J, O'Rourke E, Sims K, Walter G. Fabry Disease Practice Guidelines: Recommendations of the National Society of Genetic Counselors. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://link.springer.com/article/10.1007%2Fs10897-013-9613-3">online</ext-link>. 2013. Accessed 3-22-17.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="fabry.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="fabry.Literature_Cited.reflist0">
            <ref id="fabry.REF.aerts.2008.2812">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groener</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuiper</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donker-Koopman</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strijland</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ottenhoff</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Roomen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mirzaian</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijburg</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linthorst</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vedder</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rombach</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cox-Brinkman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Somerharju</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boot</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brady</surname>
                    <given-names>RO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poorthuis</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <article-title>Elevated globotriaosylsphingosine is a hallmark of Fabry disease.</article-title>
                <source>Proc Natl Acad Sci U S A.</source>
                <year>2008</year>
                <volume>105</volume>
                <fpage>2812</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18287059</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.allen.2010.1602">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cosgrave</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kersey</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramaswami</surname>
                    <given-names>U</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity.</article-title>
                <source>Br J Ophthalmol.</source>
                <volume>94</volume>
                <fpage>1602</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">20576773</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.ashtonprolla.2000.227">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ashton-Prolla</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tong</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shabbeer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astrin</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes.</article-title>
                <source>J Investig Med</source>
                <volume>48</volume>
                <fpage>227</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">10916280</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.aurayblais.2015.195">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Auray-Blais</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blais</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramaswami</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boutin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dyack</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bodamer</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pintos-Morell</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bichet</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warnock</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Echevarria</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lavoie</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.</article-title>
                <source>Clin Chim Acta.</source>
                <year>2015</year>
                <volume>438</volume>
                <fpage>195</fpage>
                <lpage>204</lpage>
                <pub-id pub-id-type="pmid">25149322</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.banikazemi.2007.77">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Banikazemi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bultas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waldek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whitley</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finkel</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Packman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bichet</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warnock</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.</article-title>
                <source>Ann Intern Med</source>
                <volume>146</volume>
                <fpage>77</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">17179052</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.beck.2015.21">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kampmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larroque</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pintos-Morell</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramaswami</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijatyk</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giugliani</surname>
                    <given-names>R</given-names>
                  </name>
                  <collab>Fabry Outcome Survey Study Group</collab>
                </person-group>
                <article-title>Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis.</article-title>
                <source>Mol Genet Metab Rep.</source>
                <year>2015</year>
                <volume>3</volume>
                <fpage>21</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">26937390</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.bekri.2005.c33">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bekri</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enica</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghafari</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plaza</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Champenois</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choukroun</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Unwin</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaeger</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Fabry disease in patients with end-stage renal failure: the potential benefits of screening.</article-title>
                <source>Nephron Clin Pract</source>
                <volume>101</volume>
                <fpage>c33</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15886492</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.bernstein.1989.1390">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bernstein</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bishop</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astrin</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kornreich</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakuraba</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene.</article-title>
                <source>J Clin Invest.</source>
                <year>1989</year>
                <volume>83</volume>
                <fpage>1390</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">2539398</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.biegstraaten.2015.36">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Biegstraaten</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arngr&#x000ed;msson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbey</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boks</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cecchi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deegan</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feldt-Rasmussen</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geberhiwot</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hendriksz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kantola</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karabul</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lavery</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linthorst</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van de Mheen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oliveira</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramaswami</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudnicki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serra</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sommer</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunder-Plassmann</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Svarstad</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sweeb</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terryn</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tylki-Szymanska</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>T&#x000f8;ndel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vujkovac</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weidemann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wijburg</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woolfson</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <article-title>Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2015</year>
                <volume>10</volume>
                <fpage>36</fpage>
                <pub-id pub-id-type="pmid">25885911</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.brouns.2010.863">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brouns</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thijs</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eyskens</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van den Broeck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belachew</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Broeckhoven</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Redondo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hemelsoet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fumal</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeangette</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verslegers</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baker</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Deyn</surname>
                    <given-names>PP</given-names>
                  </name>
                </person-group>
                <article-title>BeFaS Investigators. Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease.</article-title>
                <source>Stroke.</source>
                <year>2010</year>
                <volume>41</volume>
                <fpage>863</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20360539</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.cabrerasalazar.2005.102">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cabrera-Salazar</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Rourke</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charria-Ortiz</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barranger</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Radiological evidence of early cerebral microvascular disease in young children with Fabry disease.</article-title>
                <source>J Pediatr</source>
                <volume>147</volume>
                <fpage>102</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16027705</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.callegaro.2006.27">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Callegaro</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaimen-Maciel</surname>
                    <given-names>DR</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Fabry's disease as a differential diagnosis of MS.</article-title>
                <source>Int MS J.</source>
                <volume>13</volume>
                <fpage>27</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">16420782</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.cole.2007.943">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deegan</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waldek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachmann</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <article-title>Depression in adults with Fabry disease: a common and under-diagnosed problem.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2007</year>
                <volume>30</volume>
                <fpage>943</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">17994284</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.deegan.2006.347">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Deegan</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baehner</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barba Romero</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kampmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Natural history of Fabry disease in females in the Fabry Outcome Survey.</article-title>
                <source>J Med Genet</source>
                <volume>43</volume>
                <fpage>347</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">16227523</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.desnick.2003.338">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brady</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barranger</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grabowski</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Packman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.</article-title>
                <source>Ann Intern Med</source>
                <volume>138</volume>
                <fpage>338</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">12585833</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.desnick.2001">
              <mixed-citation publication-type="book">Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Kinzler KE, Vogelstein B, eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Diseases</italic>. 8 ed. New York, NY: McGraw-Hill; 2001:3733-74</mixed-citation>
            </ref>
            <ref id="fabry.REF.desnick.2002.954">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schuchman</surname>
                    <given-names>EH</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Enzyme replacement and enhancement therapies: lessons from lysosomal disorders.</article-title>
                <source>Nat Rev Genet.</source>
                <volume>3</volume>
                <fpage>954</fpage>
                <lpage>66</lpage>
                <pub-id pub-id-type="pmid">12459725</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.dobrovoln_.2005.84">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dobrovoln&#x000fd;</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dvor&#x000e1;kov&#x000e1;</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ledvinov&#x000e1;</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magage</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bultas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lubanda</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poupetov&#x000e1;</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elleder</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karetov&#x000e1;</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hreb&#x000ed;cek</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Recurrence of Fabry disease as a result of paternal germline mosaicism for alpha-galactosidase a gene mutation.</article-title>
                <source>Am J Med Genet A.</source>
                <volume>134A</volume>
                <fpage>84</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15712198</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.echevarria.2016.44">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Echevarria</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benistan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toussaint</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubourg</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagege</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eladari</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jabbour</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beldjord</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Mazancourt</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>DP</given-names>
                  </name>
                </person-group>
                <article-title>X-chromosome inactivation in female patients with Fabry disease.</article-title>
                <source>Clin Genet.</source>
                <year>2016</year>
                <volume>89</volume>
                <fpage>44</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">25974833</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.eng.2007.184">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fletcher</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waldek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sillence</surname>
                    <given-names>DO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breunig</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charrow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholls</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banikazemi</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>30</volume>
                <fpage>184</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">17347915</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.eng.2006.539">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banikazemi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warnock</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanner</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopkin</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bultas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sims</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brodie</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strotmann</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.</article-title>
                <source>Genet Med</source>
                <volume>8</volume>
                <fpage>539</fpage>
                <lpage>48</lpage>
                <pub-id pub-id-type="pmid">16980809</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.eng.2001.9">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guffon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waldek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caplan</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linthorst</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease.</article-title>
                <source>N Engl J Med</source>
                <volume>345</volume>
                <fpage>9</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">11439963</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.fan.1999.112">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fan</surname>
                    <given-names>JQ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishii</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asano</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.</article-title>
                <source>Nat Med</source>
                <volume>5</volume>
                <fpage>112</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">9883849</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.ferreira.2015.248">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferreira</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ortiz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viana-Baptista</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caldeira-Gomes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camprecios</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fenollar-Cort&#x000e9;s</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallegos-Villalobos</surname>
                    <given-names>&#x000c1;</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-Robles</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Egido</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guti&#x000e9;rrez-Rivas</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herrero</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mas</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oancea</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>P&#x000e9;res</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salazar-Mart&#x000ed;n</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solera-Garcia</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alves</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garman</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oliveira</surname>
                    <given-names>JP</given-names>
                  </name>
                </person-group>
                <article-title>The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2015</year>
                <volume>114</volume>
                <fpage>248</fpage>
                <lpage>58</lpage>
                <pub-id pub-id-type="pmid">25468652</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.froissart.2003.307">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Froissart</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guffon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanier</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maire</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma.</article-title>
                <source>Mol Genet Metab</source>
                <volume>80</volume>
                <fpage>307</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">14680977</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.frustaci.2001.25">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Frustaci</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chimenti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricci</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Natale</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russo</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pieroni</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy.</article-title>
                <source>N Engl J Med</source>
                <volume>345</volume>
                <fpage>25</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">11439944</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.gal.2012.20">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gal</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winchester</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Clinical utility gene card for: Fabry disease.</article-title>
                <source>Eur J Hum Genet.</source>
                <fpage>20</fpage>
                <pub-id pub-id-type="pmid">21811303</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.gal.2011.509">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gal</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winchester</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2011</year>
                <volume>34</volume>
                <fpage>509</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">21229318</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.galanos.2002.575">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Galanos</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholls</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grigg</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiers</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crawford</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Clinical features of Fabry's disease in Australian patients.</article-title>
                <source>Intern Med J</source>
                <volume>32</volume>
                <fpage>575</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">12512750</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.germain.2015.353">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charrow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guffon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kempf</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachmann</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemay</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linthorst</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Packman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waldek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warnock</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinreb</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                </person-group>
                <article-title>Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease.</article-title>
                <source>J Med Genet.</source>
                <year>2015</year>
                <volume>52</volume>
                <fpage>353</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">25795794</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.germain.2013.958">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weidemann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abiose</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cizmarik</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beitner-Johnson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benistan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabrera</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charrow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kantola</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linhart</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholls</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niemann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sims</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waldek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warnock</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strotmann</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Fabry Registry. Analysis of left ventricular mass in untreated men and in men treated with agalsidase-&#x003b2;: data from the Fabry Registry.</article-title>
                <source>Genet Med.</source>
                <year>2013</year>
                <volume>15</volume>
                <fpage>958</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">23703683</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.ginsberg.2006.57">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ginsberg</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manara</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valentine</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kendall</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burlina</surname>
                    <given-names>AP</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Magnetic resonance imaging changes in Fabry disease.</article-title>
                <source>Acta Paediatr Suppl.</source>
                <volume>95</volume>
                <fpage>57</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">16720467</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.gokeralpan.2016.95">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Goker-Alpan</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gambello</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maegawa</surname>
                    <given-names>GH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nedd</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gruskin</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blankstein</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weinreb</surname>
                    <given-names>NJ</given-names>
                  </name>
                </person-group>
                <article-title>Reduction of plasma globotriaosylsphingosine levels after switching from agalsidase alfa to agalsidase beta as enzyme replacement therapy for Fabry disease.</article-title>
                <source>JIMD Rep.</source>
                <year>2016</year>
                <volume>25</volume>
                <fpage>95</fpage>
                <lpage>106</lpage>
                <pub-id pub-id-type="pmid">26303609</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.gupta.2005.261">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gupta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ries</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kotsopoulos</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiffmann</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women.</article-title>
                <source>Medicine (Baltimore)</source>
                <volume>84</volume>
                <fpage>261</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16148726</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.hegemann.2006.654">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hegemann</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hajioff</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunder-Plassmann</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Widmer</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keilmann</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Hearing loss in Fabry disease: data from the Fabry Outcome Survey.</article-title>
                <source>Eur J Clin Invest</source>
                <volume>36</volume>
                <fpage>654</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">16919049</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.hoffmann.2007.1447">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keshav</surname>
                    <given-names>S</given-names>
                  </name>
                  <collab>Fabry Outcome Survey European Investigators</collab>
                </person-group>
                <year>2007</year>
                <article-title>Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy.</article-title>
                <source>Clin Gastroenterol Hepatol.</source>
                <volume>5</volume>
                <fpage>1447</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">17919989</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.hsu.2014.96">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hsu</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sung</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>FP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>HY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gao</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liao</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiang</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>CY</given-names>
                  </name>
                </person-group>
                <article-title>Yu WC1, Niu DM. Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4&#x02009;+&#x02009;919G&#x02009;&#x0003e;&#x02009;A).</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2014</year>
                <volume>9</volume>
                <fpage>96</fpage>
                <pub-id pub-id-type="pmid">24980630</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.hughes.2008.153">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliott</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shah</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zuckerman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coghlan</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brookes</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>AB</given-names>
                  </name>
                </person-group>
                <article-title>Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.</article-title>
                <source>Heart.</source>
                <year>2008</year>
                <month>Feb</month>
                <volume>94</volume>
                <issue>2</issue>
                <fpage>153</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17483124</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.ichinose.2005.228">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ichinose</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakayama</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Utsunomiya</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eto</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Significance of screening for Fabry disease among male dialysis patients.</article-title>
                <source>Clin Exp Nephrol.</source>
                <volume>9</volume>
                <fpage>228</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">16189631</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.ishii.2004.250">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ishii</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshioka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kulkarni</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fan</surname>
                    <given-names>JQ</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.</article-title>
                <source>Biochim Biophys Acta.</source>
                <volume>1690</volume>
                <fpage>250</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15511632</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.kampmann.2005.15">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kampmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baehner</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whybra</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bajbouj</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baron</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knuf</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiethoff</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tr&#x000fc;bel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>The right ventricle in Fabry disease.</article-title>
                <source>Acta Paediatr Suppl.</source>
                <volume>94</volume>
                <fpage>15</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15895706</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.kleinert.2006.782">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kleinert</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dehout</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarting</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lorenzo</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricci</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kampmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramaswami</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linhart</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gal</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houge</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Widmer</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunder-Plassmann</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Prevalence of uncontrolled hypertension in patients with Fabry disease.</article-title>
                <source>Am J Hypertens.</source>
                <volume>19</volume>
                <fpage>782</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16876675</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.kornreich.1990.9319">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kornreich</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bishop</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Alpha-galactosidase A gene rearrangements causing Fabry disease. Identification of short direct repeats at breakpoints in an Alu-rich gene.</article-title>
                <source>J Biol Chem.</source>
                <year>1990</year>
                <volume>265</volume>
                <fpage>9319</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">2160973</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.laney.2013.555">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Laney</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fox</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopkin</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Rourke</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sims</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walter</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Fabry Disease Practice Guidelines: Recommendations of the National Society of Genetic Counselors.</article-title>
                <source>J Genet Couns.</source>
                <year>2013</year>
                <volume>22</volume>
                <fpage>555</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">23860966</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.lenders.2015.1009">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lenders</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karabul</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duning</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitz</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schelleckes</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mesters</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hense</surname>
                    <given-names>HW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brand</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brand</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Thromboembolic events in Fabry disease and the impact of factor V Leiden.</article-title>
                <source>Neurology.</source>
                <year>2015</year>
                <volume>84</volume>
                <fpage>1009</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">25663229</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.lidove.2012.571">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lidove</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaminsky</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hachulla</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leguy-Seguin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lavigne</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marie</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maillot</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serratrice</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masseau</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ch&#x000e9;rin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabane</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noel</surname>
                    <given-names>E</given-names>
                  </name>
                  <collab>FIMeD investigators</collab>
                </person-group>
                <article-title>Fabry disease 'The New Great Imposter': results of the French Observatoire in Internal Medicine Departments (FIMeD).</article-title>
                <source>Clin Genet</source>
                <year>2012</year>
                <volume>81</volume>
                <fpage>571</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">21623772</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.lidove.2006.1053">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lidove</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramaswami</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaussaud</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbey</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maisonobe</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caillaud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunder-Plassmann</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linhart</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey.</article-title>
                <source>Int J Clin Pract.</source>
                <volume>60</volume>
                <fpage>1053</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16939546</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.lin.2009.450">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>HY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chong</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hsu</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shih</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chiang</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ho</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kao</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheng</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hsueh</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niu</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <article-title>High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population.</article-title>
                <source>Circ Cardiovasc Genet.</source>
                <year>2009</year>
                <volume>2</volume>
                <fpage>450</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20031620</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.linhart.2007.1228">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Linhart</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kampmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zamorano</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunder-Plassmann</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliott</surname>
                    <given-names>PM</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.</article-title>
                <source>Eur Heart J.</source>
                <volume>28</volume>
                <fpage>1228</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">17483538</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.linthorst.2005.201">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Linthorst</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vedder</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers.</article-title>
                <source>Clin Chim Acta.</source>
                <volume>353</volume>
                <fpage>201</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">15698608</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.liu.2015.107">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perrin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hsu</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lin</surname>
                    <given-names>HY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niu</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <article-title>Age at first cardiac symptoms in Fabry disease: association with a Chinese hotspot Fabry mutation (IVS4+919G&#x0003e;A), classical Fabry mutations, and sex in a Taiwanese population from the Fabry Outcome Survey (FOS).</article-title>
                <source>JIMD Rep.</source>
                <year>2015</year>
                <volume>22</volume>
                <fpage>107</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">25762495</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.l_hle.2015.1454">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>L&#x000f6;hle</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milligan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richfield</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reichmann</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schapira</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <article-title>Clinical prodromes of neurodegeneration in Anderson-Fabry disease.</article-title>
                <source>Neurology.</source>
                <year>2015</year>
                <volume>84</volume>
                <fpage>1454</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">25762709</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.lubanda.2009.256">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lubanda</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anijalg</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bzd&#x000fa;ch</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thurberg</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000e9;nichou</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tylki-Szymanska</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease.</article-title>
                <source>Genet Med.</source>
                <year>2009</year>
                <volume>11</volume>
                <fpage>256</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">19265719</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.lukas.2016.43">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lukas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scalia</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eichler</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pockrandt</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dehn</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cozma</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giese</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolfs</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Functional and Clinical Consequences of Novel &#x003b1;-Galactosidase A Mutations in Fabry Disease.</article-title>
                <source>Hum Mutat.</source>
                <year>2016</year>
                <volume>37</volume>
                <fpage>43</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">26415523</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.macdermot.2001.769">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>MacDermot</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miners</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.</article-title>
                <source>J Med Genet.</source>
                <volume>38</volume>
                <fpage>769</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">11732485</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.magage.2007.790">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Magage</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lubanda</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Susa</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bultas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karetova</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dobrovolny</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hrebicek</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linhart</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Natural history of the respiratory involvement in Anderson-Fabry disease.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>30</volume>
                <fpage>790</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17619837</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.martinez.2007.365">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Martinez</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aggio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rozenfeld</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>High incidence of autoantibodies in Fabry disease patients.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>30</volume>
                <fpage>365</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17458709</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.mechtler.2012.335">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mechtler</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stary</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Metz</surname>
                    <given-names>TF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jes&#x000fa;s</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greber-Platzer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pollak</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herkner</surname>
                    <given-names>KR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Streubel</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kasper</surname>
                    <given-names>DC</given-names>
                  </name>
                </person-group>
                <article-title>Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria.</article-title>
                <source>Lancet.</source>
                <year>2012</year>
                <volume>379</volume>
                <fpage>335</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">22133539</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.mehta.2009.548">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giugliani</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliott</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linhart</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunder-Plassmann</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Investigators</surname>
                    <given-names>FOS</given-names>
                  </name>
                </person-group>
                <article-title>Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey.</article-title>
                <source>J Med Genet.</source>
                <year>2009</year>
                <volume>46</volume>
                <fpage>548</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">19473999</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.mehta.2004.236">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ricci</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Widmer</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dehout</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia de Lorenzo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kampmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linhart</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunder-Plassmann</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ries</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.</article-title>
                <source>Eur J Clin Invest</source>
                <volume>34</volume>
                <fpage>236</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">15025684</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.meikle.1999.249">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meikle</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopwood</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clague</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carey</surname>
                    <given-names>WF</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Prevalence of lysosomal storage disorders.</article-title>
                <source>JAMA</source>
                <volume>281</volume>
                <fpage>249</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">9918480</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.moon.2003.2151">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moon</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sachdev</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elkington</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKenna</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pennell</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leed</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliott</surname>
                    <given-names>PM</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.</article-title>
                <source>Eur Heart J.</source>
                <volume>24</volume>
                <fpage>2151</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">14643276</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.nakao.2003.801">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nakao</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kodama</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takenaka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasumoto</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanzaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enriquez</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tei</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.</article-title>
                <source>Kidney Int.</source>
                <volume>64</volume>
                <fpage>801</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12911529</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.nguyen.2005.164">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>TT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gin</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholls</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Low</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galanos</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crawford</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre.</article-title>
                <source>Clin Experiment Ophthalmol.</source>
                <volume>33</volume>
                <fpage>164</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15807825</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.niemann.2014.8">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Niemann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolfs</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St&#x000f6;rk</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bijnens</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breunig</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ertl</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanner</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weidemann</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease.</article-title>
                <source>Circ Cardiovasc Genet.</source>
                <year>2014</year>
                <volume>7</volume>
                <fpage>8</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">24395922</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.odler.2016.13">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Odler</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cseh</surname>
                    <given-names>&#x000c1;</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Constantin</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fekete</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Losonczy</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tam&#x000e1;si</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benke</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szilveszter</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000fc;ller</surname>
                    <given-names>V.</given-names>
                  </name>
                </person-group>
                <article-title>Long time enzyme replacement therapy stabilizes obstructive lung disease and alters peripheral immune cell subsets in Fabry patients.</article-title>
                <source>Clin Respir J.</source>
                <year>2016</year>
                <issue>Jan</issue>
                <fpage>13</fpage>
                <comment>Epub ahead of print</comment>
                <pub-id pub-id-type="pmid">26763180</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.orteu.2007.331">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Orteu</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jansen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lidove</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jaussaud</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pintos-Morell</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramaswami</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunder-Plassman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>AB</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Fabry disease and the skin: data from FOS, the Fabry outcome survey.</article-title>
                <source>Br J Dermatol.</source>
                <volume>157</volume>
                <fpage>331</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17573884</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.ortiz.2016.495">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ortiz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abiose</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bichet</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabrera</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charrow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopkin</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jovanovic</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linhart</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maruti</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mauer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oliveira</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Politei</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waldek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanner</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoo</surname>
                    <given-names>HW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warnock</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <article-title>Time to treatment benefit for adult patients with Fabry disease receiving agalsidase &#x003b2;: data from the Fabry Registry.</article-title>
                <source>J Med Genet.</source>
                <year>2016</year>
                <volume>53</volume>
                <fpage>495</fpage>
                <lpage>502</lpage>
                <pub-id pub-id-type="pmid">26993266</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.pan.2016.e0161330">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pan</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ouyang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ren</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ni</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>N.</given-names>
                  </name>
                </person-group>
                <article-title>Genotype: A Crucial but Not Unique Factor Affecting the Clinical Phenotypes in Fabry Disease.</article-title>
                <source>PLoS One.</source>
                <year>2016</year>
                <volume>11</volume>
                <fpage>e0161330</fpage>
                <pub-id pub-id-type="pmid">27560961</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.patel.2015.961">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Mahony</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahman</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coats</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliott</surname>
                    <given-names>PM</given-names>
                  </name>
                </person-group>
                <article-title>Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease.</article-title>
                <source>Heart.</source>
                <year>2015</year>
                <volume>101</volume>
                <fpage>961</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">25655062</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.pieroni.2006.1663">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pieroni</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chimenti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Cobelli</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgante</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Del Maschio</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaudio</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russo</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frustaci</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization.</article-title>
                <source>J Am Coll Cardiol</source>
                <volume>47</volume>
                <fpage>1663</fpage>
                <lpage>71</lpage>
                <pub-id pub-id-type="pmid">16631007</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.pisani.2013.41">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pisani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spinelli</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Visciano</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Capuano</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabbatini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riccio</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Messalli</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imbriaco</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease.</article-title>
                <source>JIMD Rep.</source>
                <year>2013</year>
                <volume>9</volume>
                <fpage>41</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23430546</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.pitz.2015.e0120814">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pitz</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalkum</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arash</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karabul</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sodi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larroque</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gal</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Ocular signs correlate well with disease severity and genotype in Fabry disease.</article-title>
                <source>PLoS One.</source>
                <year>2015</year>
                <volume>10</volume>
                <fpage>e0120814</fpage>
                <pub-id pub-id-type="pmid">25781336</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.politei.2006.103">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Politei</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Capizzano</surname>
                    <given-names>AA</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Magnetic resonance image findings in 5 young patients with Fabry disease.</article-title>
                <source>Neurologist.</source>
                <volume>12</volume>
                <fpage>103</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16534447</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.ramaswami.2006.86">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ramaswami</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whybra</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pintos-Morell</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunder-Plassmann</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Widmer</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey.</article-title>
                <source>Acta Paediatr.</source>
                <volume>95</volume>
                <fpage>86</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">16498740</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.ries.2003.413">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ries</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mengel</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kutschke</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>KS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birklein</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krummenauer</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Use of gabapentin to reduce chronic neuropathic pain in Fabry disease.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>26</volume>
                <fpage>413</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">12971431</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.rolfs.2005.1794">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rolfs</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bottcher</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zschiesche</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morris</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winchester</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bauer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walter</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mix</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lohr</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harzer</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strauss</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pahnke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grossmann</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benecke</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.</article-title>
                <source>Lancet.</source>
                <volume>366</volume>
                <fpage>1794</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16298216</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.rolfs.2013.340">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rolfs</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fazekas</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grittner</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dichgans</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martus</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holzhausen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000f6;ttcher</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heuschmann</surname>
                    <given-names>PU</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tatlisumak</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanislav</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jungehulsing</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giese</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Putaala</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huber</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bodechtel</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lichy</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enzinger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hennerici</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaps</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kessler</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lackner</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paschke</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mascher</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riess</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kolodny</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Norrving</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Stroke in Young Fabry Patients (sifap) Investigators. Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients Study.</article-title>
                <source>Stroke.</source>
                <year>2013</year>
                <volume>44</volume>
                <fpage>340</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23306324</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.rombach.2013.29">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rombach</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linthorst</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dijkgraaf</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <article-title>Cost-effectiveness of enzyme replacement therapy for Fabry disease.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2013</year>
                <volume>8</volume>
                <fpage>29</fpage>
                <pub-id pub-id-type="pmid">23421808</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.sachdev.2002.1407">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sachdev</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takenaka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teraguchi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tei</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKenna</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliott</surname>
                    <given-names>PM</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy.</article-title>
                <source>Circulation.</source>
                <volume>105</volume>
                <fpage>1407</fpage>
                <lpage>11</lpage>
                <pub-id pub-id-type="pmid">11914245</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.sadek.2004.199">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sadek</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shellhaas</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camfield</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camfield</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burley</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Psychiatric findings in four female carriers of Fabry disease.</article-title>
                <source>Psychiatr Genet.</source>
                <volume>14</volume>
                <fpage>199</fpage>
                <lpage>201</lpage>
                <pub-id pub-id-type="pmid">15564893</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.sado.2013.392">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sado</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piechnik</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banypersad</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Treibel</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Captur</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fontana</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maestrini</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flett</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robson</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachmann</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neubauer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliott</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moon</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <article-title>Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping.</article-title>
                <source>Circ Cardiovasc Imaging.</source>
                <year>2013</year>
                <month>May</month>
                <day>1</day>
                <volume>6</volume>
                <issue>3</issue>
                <fpage>392</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23564562</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.schaefer.2005.87">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gal</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey.</article-title>
                <source>Acta Paediatr Suppl.</source>
                <volume>94</volume>
                <fpage>87</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">15895718</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.sch_fer.2005.412">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sch&#x000e4;fer</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baron</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Widmer</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deegan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunder-Plassmann</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johansson</surname>
                    <given-names>JO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whybra</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ries</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gal</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease.</article-title>
                <source>Hum Mutat.</source>
                <volume>25</volume>
                <fpage>412</fpage>
                <pub-id pub-id-type="pmid">15776423</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.schiffmann.2007.1576">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schiffmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Askari</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmons</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benko</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brady</surname>
                    <given-names>RO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ries</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.</article-title>
                <source>J Am Soc Nephrol.</source>
                <volume>18</volume>
                <fpage>1576</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">17409308</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.schiffmann.2001.2743">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schiffmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kopp</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Austin</surname>
                    <given-names>HA</given-names>
                    <suffix>3rd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Sabnis</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weibel</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balow</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brady</surname>
                    <given-names>RO</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Enzyme replacement therapy in Fabry disease: a randomized controlled trial.</article-title>
                <source>JAMA</source>
                <volume>285</volume>
                <fpage>2743</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11386930</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.schiffmann.2015.1129">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schiffmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swift</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blankenship</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ries</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>A prospective 10-year study of individualized, intensified enzyme replacement therapy in advanced Fabry disease.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2015</year>
                <volume>38</volume>
                <fpage>1129</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">25900714</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.shah.2005.842">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shah</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sachdev</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tome</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ward</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliott</surname>
                    <given-names>PM</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.</article-title>
                <source>Am J Cardiol.</source>
                <volume>96</volume>
                <fpage>842</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16169374</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.sims.2009.788">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sims</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Politei</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banikazemi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>P.</given-names>
                  </name>
                </person-group>
                <article-title>Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.</article-title>
                <source>Stroke.</source>
                <year>2009</year>
                <volume>40</volume>
                <fpage>788</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">19150871</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.sirrs.2014.499">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sirrs</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bichet</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casey</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemoine</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doucette</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>ML</given-names>
                  </name>
                  <collab>CFDI investigators</collab>
                </person-group>
                <article-title>Outcomes of patients treated through the Canadian Fabry disease initiative.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2014</year>
                <volume>111</volume>
                <fpage>499</fpage>
                <lpage>506</lpage>
                <pub-id pub-id-type="pmid">24534763</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.smid.2011.69">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smid</surname>
                    <given-names>BE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rombach</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aerts</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuiper</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mirzaian</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Overkleeft</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poorthuis</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groener</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linthorst</surname>
                    <given-names>GE</given-names>
                  </name>
                </person-group>
                <article-title>Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2011</year>
                <volume>6</volume>
                <fpage>69</fpage>
                <pub-id pub-id-type="pmid">22041095</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.smid.2014.400">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smid</surname>
                    <given-names>BE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Tol</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cecchi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliott</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linthorst</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmermans</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weidemann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>West</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biegstraaten</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lekanne Deprez</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Florquin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Postema</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomberli</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Wal</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Bergh Weerman</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                </person-group>
                <article-title>Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance.</article-title>
                <source>Int J Cardiol.</source>
                <year>2014</year>
                <volume>177</volume>
                <fpage>400</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">25442977</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.sodi.2007.210">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sodi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ioannidis</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mehta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davey</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pitz</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey.</article-title>
                <source>Br J Ophthalmol.</source>
                <volume>91</volume>
                <fpage>210</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">16973664</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.spada.2006.31">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spada</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagliardini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasuda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tukel</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thiagarajan</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakuraba</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ponzone</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>High incidence of later-onset fabry disease revealed by newborn screening.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>79</volume>
                <fpage>31</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">16773563</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.tahir.2007.2609">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tahir</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackson</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warnock</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.</article-title>
                <source>J Am Soc Nephrol.</source>
                <volume>18</volume>
                <fpage>2609</fpage>
                <lpage>17</lpage>
                <pub-id pub-id-type="pmid">17656478</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.tanaka.2005.281">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eto</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyamura</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishida</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Araki</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itoh</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsushita</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hara</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuwahara</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakano</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yasumoto</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nonoguchi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tomita</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients.</article-title>
                <source>Clin Nephrol.</source>
                <volume>64</volume>
                <fpage>281</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16240899</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.terryn.2013.101">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Terryn</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanholder</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hemelsoet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>BP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Biesen</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Schoenmakere</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wuyts</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Claes</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Backer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Paepe</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fogo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Praet</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poppe</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <article-title>Questioning the Pathogenic Role of the GLA p.Ala143Thr "Mutation" in Fabry Disease: Implications for Screening Studies and ERT.</article-title>
                <source>JIMD Rep.</source>
                <year>2013</year>
                <volume>8</volume>
                <fpage>101</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23430526</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.tsuboi.2012.779">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tsuboi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).</article-title>
                <source>Genet Med.</source>
                <year>2012</year>
                <volume>14</volume>
                <fpage>779</fpage>
                <lpage>86</lpage>
              </element-citation>
            </ref>
            <ref id="fabry.REF.waldek.2014.72">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Waldek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feriozzi</surname>
                    <given-names>S.</given-names>
                  </name>
                </person-group>
                <article-title>Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?</article-title>
                <source>BMC Nephrol.</source>
                <year>2014</year>
                <volume>15</volume>
                <fpage>72</fpage>
                <pub-id pub-id-type="pmid">24886109</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.waldek.2009.790">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Waldek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banikazemi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemay</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry.</article-title>
                <source>Genet Med.</source>
                <year>2009</year>
                <volume>11</volume>
                <fpage>790</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19745746</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.warnock.2015.860">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Warnock</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vujkovac</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charrow</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laney</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackson</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanner</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.</article-title>
                <source>J Med Genet.</source>
                <year>2015</year>
                <volume>52</volume>
                <fpage>860</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">26490103</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.weidemann.2005.1221">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weidemann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breunig</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandstede</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stork</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voelker</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ertl</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knoll</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanner</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strotmann</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease.</article-title>
                <source>Eur Heart J.</source>
                <volume>26</volume>
                <fpage>1221</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15728649</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.weidemann.2013.331">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weidemann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niemann</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St&#x000f6;rk</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breunig</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sommer</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Herrmann</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ertl</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanner</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications.</article-title>
                <source>J Intern Med.</source>
                <year>2013</year>
                <volume>274</volume>
                <fpage>331</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">23586858</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.whitley.1983.2177">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Whitley</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsai</surname>
                    <given-names>MY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heger</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prystowsky</surname>
                    <given-names>EN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zipes</surname>
                    <given-names>DP</given-names>
                  </name>
                </person-group>
                <year>1983</year>
                <article-title>Amiodarone phenocopy of Fabry's keratopathy.</article-title>
                <source>JAMA</source>
                <volume>249</volume>
                <fpage>2177</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">6300478</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.whybra.2001.715">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Whybra</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kampmann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willers</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winchester</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kriegsmann</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruhl</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gal</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bunge</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beck</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>24</volume>
                <fpage>715</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">11804208</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.wijburg.2015.e0124987">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wijburg</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000e9;nichou</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bichet</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dostalova</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fainboim</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fellgiebel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forcelini</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>An Haack K, Hopkin RJ, Mauer M, Najafian B, Scott CR, Shankar SP, Thurberg BL, T&#x000f8;ndel C, Tylki-Szyma&#x00144;ska A, Ramaswami U. Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.</article-title>
                <source>PLoS One.</source>
                <year>2015</year>
                <volume>10</volume>
                <fpage>e0124987</fpage>
                <pub-id pub-id-type="pmid">25955246</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.wilcox.2012.443">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linthorst</surname>
                    <given-names>GE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feldt-Rasmussen</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waldek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richards</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beitner-Johnson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cizmarik</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kingma</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warnock</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <article-title>Anti-&#x003b1;-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2012</year>
                <volume>105</volume>
                <fpage>443</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22227322</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.wilcox.2008.112">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>WR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oliveira</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hopkin</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ortiz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banikazemi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feldt-Rasmussen</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sims</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waldek</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pastores</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marodi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stanford</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Breunig</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanner</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warnock</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemay</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Germain</surname>
                    <given-names>DP</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry.</article-title>
                <source>Mol Genet Metab.</source>
                <volume>93</volume>
                <fpage>112</fpage>
                <lpage>28</lpage>
                <pub-id pub-id-type="pmid">18037317</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.wozniak.2010.78">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wozniak</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kittner</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuhrim</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stern</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dobbins</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grace</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nazarenko</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dobrovolny</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDade</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke.</article-title>
                <source>Stroke.</source>
                <year>2010</year>
                <volume>41</volume>
                <fpage>78</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">20007919</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.yasuda.2003.162">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yasuda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shabbeer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Fabry disease: novel alpha-galactosidase A 3'-terminal mutations result in multiple transcripts due to aberrant 3'-end formation.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>73</volume>
                <fpage>162</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">12796853</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.zampetti.2012.712">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zampetti</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orteu</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antuzzi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bongiorno</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manco</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gnarra</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrone</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cardinali</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kovacs</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aspite</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Linder</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feliciani</surname>
                    <given-names>C</given-names>
                  </name>
                  <collab>Interdisciplinary Study Group on Fabry Disease (ISGF)</collab>
                </person-group>
                <article-title>Angiokeratoma: decision-making aid for the diagnosis of Fabry disease.</article-title>
                <source>Br J Dermatol.</source>
                <year>2012</year>
                <volume>166</volume>
                <fpage>712</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">22452439</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.ziegler.2002.935">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ziegler</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cherry</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hempel</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Rooijen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ioannou</surname>
                    <given-names>YA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldberg</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yew</surname>
                    <given-names>NS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheng</surname>
                    <given-names>SH</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease.</article-title>
                <source>Hum Gene Ther.</source>
                <volume>13</volume>
                <fpage>935</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">12031126</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.ziegler.2004.231">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ziegler</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lonning</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Armentano</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Souza</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cherry</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ford</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbon</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gao</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peluso</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Godwin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carter</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregory</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wadsworth</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheng</surname>
                    <given-names>SH</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice.</article-title>
                <source>Mol Ther.</source>
                <volume>9</volume>
                <fpage>231</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">14759807</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.ziegler.1999.1667">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ziegler</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yew</surname>
                    <given-names>NS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cherry</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berthelette</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romanczuk</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ioannou</surname>
                    <given-names>YA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeidner</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desnick</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheng</surname>
                    <given-names>SH</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.</article-title>
                <source>Hum Gene Ther.</source>
                <volume>10</volume>
                <fpage>1667</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">10428212</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.zizzo.2013.576">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zizzo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colomba</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Albeggiani</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallizzi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iemolo</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nuzzo</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vasto</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caruso</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duro</surname>
                    <given-names>G.</given-names>
                  </name>
                </person-group>
                <article-title>Misdiagnosis of familial Mediterranean fever in patients with Anderson-Fabry disease.</article-title>
                <source>Clin Genet.</source>
                <year>2013</year>
                <volume>83</volume>
                <fpage>576</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">22905681</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="fabry.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="fabry.Suggested_Reading.reflist0">
            <ref id="fabry.REF.brady.2006.283">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brady</surname>
                    <given-names>RO</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Enzyme replacement for lysosomal diseases.</article-title>
                <source>Annu Rev Med</source>
                <volume>57</volume>
                <fpage>283</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">16409150</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.desnick">
              <mixed-citation publication-type="book">Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID)</italic>. New York, NY: McGraw-Hill. Chap 150. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>.</mixed-citation>
            </ref>
            <ref id="fabry.REF.meschia.2005.122">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meschia</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brott</surname>
                    <given-names>TG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>RD</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Genetics of cerebrovascular disorders.</article-title>
                <source>Mayo Clin Proc</source>
                <volume>80</volume>
                <fpage>122</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">15667040</pub-id>
              </element-citation>
            </ref>
            <ref id="fabry.REF.ries.2005.e344">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ries</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gupta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>DF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sachdev</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quirk</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murray</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosing</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gal</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dambrosia</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garman</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brady</surname>
                    <given-names>RO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiffmann</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Pediatric Fabry disease.</article-title>
                <source>Pediatrics</source>
                <volume>115</volume>
                <fpage>e344</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">15713906</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="fabry.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="fabry.Author_History">
          <title>Author History</title>
          <p>Kenneth H Astrin, PhD; Mount Sinai School of Medicine (2001-2008) Robert J Desnick, PhD, MD; Mount Sinai School of Medicine (2001-2008) Derralynn A Hughes, MA, DPhil, FRCP, FRCPath (2008-present) Atul Mehta, MA, MD, FRCP, FRCPath (2008-present)</p>
        </sec>
        <sec id="fabry.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>5 January 2017 (sw) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>17 October 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>10 March 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>26 February 2008 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>27 August 2004 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>2 January 2004 (rd) Revision: Management - ERT</p>
            </list-item>
            <list-item>
              <p>5 August 2002 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>17 September 2001 (rd) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
